[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1450
6. Wang X, Feng Y, Liu J, Lee H, Li C, Li N, Ren N: Sequestration of CO2 discharged from anode by algal cathode in microbial carbon capture cells (MCCs). Biosens Bioelectron; 2010 Aug 15;25(12):2639-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequestration of CO2 discharged from anode by algal cathode in microbial carbon capture cells (MCCs).
  • By introducing anodic off gas into an algae grown cathode (Chlorella vulgaris), new microbial carbon capture cells (MCCs) were constructed and demonstrated here to be an effective technology for CO(2) emission reduction with simultaneous voltage output without aeration (610+/-50 mV, 1000 Omega).
  • Compared to a stable voltage of 706+/-21 mV (1000 Omega) obtained with cathodic dissolved oxygen (DO) of 6.6+/-1.0 mg/L in MCC, voltage outputs decreased from 654 to 189 mV over 70 h in the control reactor (no algae) accompanied with a decrease in DO from 7.6 to 0.9 mg/L, indicating that cathode electron acceptor was oxygen.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20547055.001).
  • [ISSN] 1873-4235
  • [Journal-full-title] Biosensors & bioelectronics
  • [ISO-abbreviation] Biosens Bioelectron
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants; 142M471B3J / Carbon Dioxide
  •  go-up   go-down


7. Pilloni L, Manieli C, Senes G, Ribuffo D, Faa G: Merkel cell carcinoma with an unusual immunohistochemical profile. Eur J Histochem; 2009 Dec 29;53(4):e33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma with an unusual immunohistochemical profile.
  • The clinical and morphological picture of Merkel cell carcinoma (MCC) may be rather challenging; therefore, the immunohistochemical profile plays a relevant role in confirming the microscopic diagnosis.
  • A panel of antibodies including cytokeratins 20, 7 and epithelial membrane antigen, and neuron-specific enolase is used in confirming the morphological diagnosis of MCC.
  • The majority of MCCs express CK20 and are CK7-negative.
  • Herein, we present a case of primary cutaneous neuroendocrine carcinoma with an atypical immunohistochemical pattern.
  • The skin tumor was excided, formalin-fixed and paraffinembedded.
  • Tissue sections were immunostained with a panel of antibodies routinely utilized in complex primary skin tumors for evidencing epithelial and neuroendocrine differentiation of tumor cells.
  • The neuroendocrine differentiation of tumor cells was evidenced by their immunoreactivity for synaptophysin, chromograninA and neuron-specific enolase.
  • Tumor cells also showed diffuse cytoplasmic staining for CK7.
  • Our data, together with previous rare reports of CK20-/CK7+ MCCs, lay stress on the importance of routinely utilizing a panel of antibodies in the differential diagnosis of complex primary carcinomas of the skin and may have important implications in expanding the differential diagnosis of skin tumors.
  • In particular, caution should be taken in excluding the diagnosis of MCC only on the basis of the absence of reactivity of tumor cells for CK20, favouring the wrong diagnosis of less aggressive skin tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Merkel Cell / chemistry. Carcinoma, Merkel Cell / pathology. Keratin-20 / analysis. Keratin-7 / analysis. Skin Neoplasms / chemistry. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Dermatopathol. 2000 Feb;22(1):65-9 [10698220.001]
  • [Cites] J Cutan Pathol. 2007 Dec;34(12):918-23 [18001414.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Dec;8(4):310-5 [11127923.001]
  • [Cites] Pathologica. 2001 Dec;93(6):640-4 [11785114.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):588-98 [11786590.001]
  • [Cites] Histopathology. 2002 Mar;40(3):230-6 [11895488.001]
  • [Cites] Am J Dermatopathol. 1980 Summer;2(2):101-19 [7246977.001]
  • [Cites] Am J Dermatopathol. 1982 Dec;4(6):497-500 [7165057.001]
  • [Cites] Pathol Annu. 1984;19 Pt 2:1-30 [6209606.001]
  • [Cites] Am J Surg Pathol. 1985 Feb;9(2):109-16 [2579592.001]
  • [Cites] Lab Invest. 1985 Apr;52(4):334-53 [2580118.001]
  • [Cites] Differentiation. 1985;30(2):165-75 [3007249.001]
  • [Cites] Dermatologica. 1988;177(1):1-10 [3141225.001]
  • [Cites] J Invest Dermatol. 1995 Jun;104(6):910-5 [7769257.001]
  • [Cites] Exp Dermatol. 1995 Dec;4(6):365-71 [8608344.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2589-95 [10375107.001]
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):5 [15611999.001]
  • [Cites] Am J Dermatopathol. 2006 Apr;28(2):99-104 [16625069.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2493-9 [10856110.001]
  • (PMID = 22073365.001).
  • [ISSN] 2038-8306
  • [Journal-full-title] European journal of histochemistry : EJH
  • [ISO-abbreviation] Eur J Histochem
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Keratin-7
  • [Other-IDs] NLM/ PMC3167334
  • [Keywords] NOTNLM ; CK20 negative / CK7 positive. / Merkel cell carcinoma / immunohistochemical profile
  •  go-up   go-down


8. Takahashi I, Onodera K, Bae JW, Mitani H, Sasano Y, Mitani H: Age-related changes in the expression of gelatinase and tissue inhibitor of metalloproteinase genes in mandibular condylar, growth plate, and articular cartilage in rats. J Mol Histol; 2005 Jun;36(5):355-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-related changes in the expression of gelatinase and tissue inhibitor of metalloproteinase genes in mandibular condylar, growth plate, and articular cartilage in rats.
  • Mandibular condylar cartilage acts as both articular and growth plate cartilage during growth, and then becomes articular cartilage after growth is complete.
  • This study attempted to clarify the age-related changes in the mRNA expression patterns of MMP-2, MMP-9, TIMP-1, TIMP-2, and TIMP-3 in mandibular condylar cartilage in comparison to tibial growth plate and articular cartilage using an in situ hybridization method in growing and adult rats.
  • MMP-2 and MMP-9 were expressed in a wide range of condylar cartilage cells during growth, and their expression domains became limited to mature chondrocytes in adults.
  • Therefore, we concluded that TIMP-1 and TIMP-2 were general inhibitors of MMP-2 and MMP-9 in condylar cartilage, while TIMP-3 regulates the collagenolytic degradation of the hypertrophic cartilage matrix.
  • [MeSH-major] Aging / metabolism. Cartilage, Articular / metabolism. Gelatinases / metabolism. Growth Plate / metabolism. Mandibular Condyle / metabolism. Tissue Inhibitor of Metalloproteinases / metabolism

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2001;7(1):14-23 [11349215.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):12501-4 [11278243.001]
  • [Cites] J Biol Chem. 1996 Jan 19;271(3):1544-50 [8576151.001]
  • [Cites] Cell Tissue Res. 2000 Dec;302(3):343-52 [11151446.001]
  • [Cites] Anat Embryol (Berl). 1996 Nov;194(5):489-500 [8905015.001]
  • [Cites] Acta Anat (Basel). 1992;144(1):59-64 [1514361.001]
  • [Cites] Crit Rev Oral Biol Med. 1993;4(2):197-250 [8435466.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):657-72 [12209155.001]
  • [Cites] Biochim Biophys Acta. 1996 Dec 12;1314(3):226-32 [8982276.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21491-4 [10419448.001]
  • [Cites] Histochem Cell Biol. 2003 Jul;120(1):23-32 [12827373.001]
  • [Cites] J Rheumatol. 1999 Mar;26(3):717-9 [10090189.001]
  • [Cites] Science. 1999 Jun 4;284(5420):1664-6 [10356395.001]
  • [Cites] J Histochem Cytochem. 2002 Mar;50(3):325-32 [11850435.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 7;1477(1-2):267-83 [10708863.001]
  • [Cites] Histochemistry. 1990;93(6):593-9 [2184152.001]
  • [Cites] J Biol Chem. 1981 Sep 25;256(18):9511-5 [6270089.001]
  • [Cites] Anat Embryol (Berl). 1996 Sep;194(3):247-52 [8849671.001]
  • [Cites] J Anat. 2003 Aug;203(2):235-41 [12924823.001]
  • [Cites] Lab Invest. 1996 Jan;74(1):232-40 [8569187.001]
  • [Cites] J Biol Chem. 1981 May 10;256(9):4662-8 [6260809.001]
  • [Cites] J Neurosci Res. 2002 Jul 1;69(1):1-9 [12111810.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6B):4207-19 [11908674.001]
  • [Cites] J Biol Chem. 1990 Dec 15;265(35):21929-34 [2174891.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Eur J Biochem. 1997 Dec 15;250(3):751-7 [9461298.001]
  • [Cites] J Oral Pathol Med. 2005 Jan;34(1):39-45 [15610405.001]
  • [Cites] APMIS. 1999 Jan;107(1):137-43 [10190290.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:463-516 [11687497.001]
  • [Cites] Plast Reconstr Surg. 2000 Mar;105(3):980-90 [10724258.001]
  • [Cites] J Anat. 1997 Nov;191 ( Pt 4):561-70 [9449075.001]
  • [Cites] J Biol Chem. 1991 Feb 5;266(4):2017-20 [1846608.001]
  • [Cites] J Biol Chem. 1981 Sep 25;256(18):9516-21 [6270090.001]
  • [Cites] J Anat. 1999 Oct;195 ( Pt 3):321-9 [10580848.001]
  • [Cites] J Histochem Cytochem. 1992 Aug;40(8):1139-46 [1619278.001]
  • [Cites] Biorheology. 2002;39(1-2):237-46 [12082286.001]
  • [Cites] J Biol Chem. 1992 Sep 25;267(27):19470-4 [1326552.001]
  • [Cites] Braz J Med Biol Res. 1996 Sep;29(9):1087-97 [9181050.001]
  • [Cites] Histochem Cell Biol. 2000 Aug;114(2):157-65 [11052264.001]
  • [Cites] J Bone Miner Metab. 2002;20(3):142-7 [11984696.001]
  • [Cites] J Anat. 1990 Jun;170:11-22 [2254157.001]
  • [Cites] J Cell Biol. 1990 Apr;110(4):1369-78 [1691190.001]
  • [Cites] J Am Podiatr Med Assoc. 2002 Jan;92(1):12-8 [11796794.001]
  • [Cites] Cytokine. 2001 Oct 7;16(1):31-5 [11669584.001]
  • [Cites] FEBS Lett. 2001 Apr 13;494(3):192-5 [11311239.001]
  • (PMID = 16208432.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


9. Rothe JH, Denecke T, Röttgen R: [Merkel cell carcinoma: a rare tumor entity in an unusually young patient]. Rofo; 2009 Mar;181(3):270-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Merkel cell carcinoma: a rare tumor entity in an unusually young patient].
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / diagnosis. Positron-Emission Tomography. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Contrast Media. Disease Progression. Fatal Outcome. Fluorodeoxyglucose F18. Humans. Knee / surgery. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Surgical Flaps. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19229796.001).
  • [ISSN] 1438-9010
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


10. Liao C, Yang X, Li FT, Li J, Li DZ: The detection of aneuploidy and maternal contamination by QF-PCR in samples undergoing prenatal diagnosis for thalassemia in Southern China. Eur J Obstet Gynecol Reprod Biol; 2009 Jun;144(2):149-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The detection of aneuploidy and maternal contamination by QF-PCR in samples undergoing prenatal diagnosis for thalassemia in Southern China.
  • OBJECTIVES: To apply a simple and low-cost approach, which would easily and accurately detect both the common chromosomal abnormalities and maternal cell contamination (MCC) when invasive prenatal testing is performed for diagnosis of thalassemia.
  • Five (1.3%) samples showed MCC, including two (0.7%, 2/289) amniotic fluid samples and three (3.1%; 3/98) chorionic villi samples.
  • Of the 379 prenatal samples without MCC, QF-PCR assays detected two (0.5%) cases of trisomy 21, which were confirmed by traditional karyotyping, and missed one case of trisomy 2 mosaicism and one case of monosomy X.
  • There was no clinically significant case that would have been missed if QF-PCR had been used as a stand-alone test instead of karyotyping when invasive prenatal testing was performed for diagnosis of thalassaemia.
  • CONCLUSIONS: The QF-PCR assay could allow simultaneous detection of aneuploidy and possible MCC in the fetal material.
  • This strategy may be applied to prenatal diagnosis of other recessive disorders.
  • [MeSH-major] Aneuploidy. Polymerase Chain Reaction / methods. Prenatal Diagnosis / methods
  • [MeSH-minor] Adult. China. Female. Humans. Pregnancy. Prospective Studies. Specimen Handling / methods. Thalassemia / diagnosis. Young Adult

  • Genetic Alliance. consumer health - Thalassemia.
  • MedlinePlus Health Information. consumer health - Prenatal Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19375212.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


11. Kristensen J: Direct pelletization in a rotary processor controlled by torque measurements. III. Investigation of microcrystalline cellulose and lactose grade. AAPS PharmSciTech; 2005;6(3):E495-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to investigate the use of different grades of microcrystalline cellulose (MCC) and lactose in a direct pelletization process in a rotary processor.
  • For this purpose, a mixed 2- and 3-level factorial study was performed to determine the influence of the particle size of microcrystalline cellulose (MCC) (approximately 60 and 105 microm) and lactose (approximately 30, 40, and 55 microm), as well as MCC type (Avicel and Emcocel) on the pelletization process and the physical properties of the prepared pellets.
  • A 1:4 mixture of MCC and lactose was applied, and granulation liquid was added until a 0.45 Nm increase in the torque of the friction plate was reached.
  • The particle size of MCC was found to have no marked effect on the amount of water required for agglomerate growth or on the size of the resulting pellets.
  • The MCC type was found to affect both the release of the model drug from the prepared pellets and the size distribution.
  • Generally, the determined influence of the investigated factors was small, and direct pelletization in a rotary processor was found to be a robust process, insensitive to variations in the particle size and type of MCC and the particle size of lactose.

  • Hazardous Substances Data Bank. Lactose .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drug Dev Ind Pharm. 2002 Nov;28(10):1201-12 [12476866.001]
  • [Cites] AAPS PharmSciTech. 2000;1(4):E35 [14727900.001]
  • [Cites] AAPS PharmSci. 2000;2(3):E24 [11741240.001]
  • [Cites] Pharm Res. 1997 Jun;14(6):804-9 [9210201.001]
  • [Cites] Pharm Dev Technol. 2000;5(2):247-56 [10810754.001]
  • [Cites] Drug Dev Ind Pharm. 2004 Feb;30(2):111-23 [15089045.001]
  • (PMID = 16354010.001).
  • [ISSN] 1530-9932
  • [Journal-full-title] AAPS PharmSciTech
  • [ISO-abbreviation] AAPS PharmSciTech
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Implants; 0 / microcrystalline cellulose; 9004-34-6 / Cellulose; J2B2A4N98G / Lactose
  • [Other-IDs] NLM/ PMC2750396
  •  go-up   go-down


12. Köksal Y, Toy H, Talim B, Unal E, Akçören Z, Cengiz M: Merkel cell carcinoma in a child. J Pediatr Hematol Oncol; 2009 May;31(5):359-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma in a child.
  • Merkel cell carcinoma, a rare tumor of the skin with aggressive behavior, is usually fatal when advanced disease is present.
  • Merkel cell carcinoma occurs mostly in white race between 60 and 80 years of age, however, it can occur in any races and ages.
  • We present here a Merkel cell carcinoma in a boy.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415020.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Kumar M, Gromiha MM, Raghava GP: Prediction of RNA binding sites in a protein using SVM and PSSM profile. Proteins; 2008 Apr;71(1):189-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • First, a SVM model was developed that achieved a maximum Matthew's correlation coefficient (MCC) of 0.31.
  • The performance of this SVM model further improved the MCC from 0.31 to 0.45, when multiple sequence alignment in the form of PSSM profiles was used as input to the SVM, which is far better than the maximum MCC achieved by previous methods (0.41) on the same dataset.
  • Utilizing PSSM as input information to the SVM, the training/testing on this alternate dataset achieved a maximum MCC of 0.32.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17932917.001).
  • [ISSN] 1097-0134
  • [Journal-full-title] Proteins
  • [ISO-abbreviation] Proteins
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA-Binding Proteins; 63231-63-0 / RNA
  •  go-up   go-down


1
Advertisement
4. Yoon J, Kang Y, Kim K, Park J, Kim Y: Identification and purification of a soluble region of BubR1: a critical component of the mitotic checkpoint complex. Protein Expr Purif; 2005 Nov;44(1):1-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mitotic checkpoint complex (MCC) ensures the fidelity of chromosomal segregation, by delaying the onset of anaphase until all sister chromatids have been properly attached to the mitotic spindle.
  • In essence, this MCC-induced delay is achieved via the inhibition of the anaphase-promoting complex (APC).
  • Among the components of the MCC, BubR1 plays two major roles in the functions of the mitotic checkpoint.
  • First, BubR1 is able to inhibit APC activity, either by itself or as a component of the MCC, by sequestering a APC coactivator, known as Cdc20.
  • Third, we optimized the solubility of the two constructs by either chopping or adding a few residues at the C-terminus.
  • Finally, we obtained a highly soluble BubR1 construct via the Escherichia coli expression system, which allowed for a yield of 10.8 mg/L culture.
  • [MeSH-minor] Amino Acid Motifs / genetics. Amino Acid Sequence. Animals. Cdc20 Proteins. Cell Cycle Proteins / metabolism. Chromosome Segregation / physiology. Cloning, Molecular / methods. Genetic Vectors / genetics. Molecular Sequence Data. Protein Binding / physiology. Protein Structure, Tertiary. Protein-Serine-Threonine Kinases. Rats. Solubility

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946858.001).
  • [ISSN] 1046-5928
  • [Journal-full-title] Protein expression and purification
  • [ISO-abbreviation] Protein Expr. Purif.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdc20 Proteins; 0 / Cell Cycle Proteins; 156288-95-8 / CDC20 protein, human; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / BUB1 protein, human; EC 2.7.11.1 / Bub1 spindle checkpoint protein; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


15. Koljonen V: Merkel cell carcinoma. World J Surg Oncol; 2006;4:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma.
  • BACKGROUND: Merkel cell carcinoma (MCC) is an unusual primary neuroendocrine carcinoma of the skin.
  • MCC is a fatal disease, and patients have a poor chance of survival.
  • Moreover, MCC lacks distinguishing clinical features, and thus by the time the diagnosis is made, the tumour usually have metastasized.
  • MCC mainly affects sun-exposed areas of elderly persons.
  • METHODS: MCC was first described in 1972.
  • Since then, most of the cases reported, have been in small series of patients.
  • The present study reviews the world literature on MCC.
  • The purpose of this article is to shed light on this unknown neuroendocrine carcinoma and provide the latest information on prognostic markers and treatment options.
  • RESULTS: The epidemiological studies have revealed that large tumour size, male sex, truncal site, nodal/distant disease at presentation, and duration of disease before presentation, are poor prognostic factors.
  • During the last few years, the research on MCC has produced prognostic markers, which can be translated into clinical patient care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):1-4 [15611998.001]
  • [Cites] Head Neck. 2005 Mar;27(3):208-16 [15627249.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2300-9 [15800320.001]
  • [Cites] J Ultrastruct Res. 1971 Mar;34(5):464-72 [4324460.001]
  • [Cites] Arch Dermatol. 1972 Jan;105(1):107-10 [5009611.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2A):853-8 [15868919.001]
  • [Cites] ANZ J Surg. 2005 May;75(5):275-81 [15932436.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2005 May;114(5):376-80 [15966524.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Jul;131(7):610-4 [16027284.001]
  • [Cites] J Dermatol Surg Oncol. 1992 May;18(5):375-80 [1607460.001]
  • [Cites] BMC Cancer. 2005;5:106 [16111484.001]
  • [Cites] J Cutan Pathol. 2005 Sep;32(8):541-5 [16115052.001]
  • [Cites] Diagn Cytopathol. 1990;6(1):53-7 [1691073.001]
  • [Cites] Lab Invest. 1990 Aug;63(2):233-41 [1696332.001]
  • [Cites] APMIS. 1990 Aug;98(8):741-52 [1698390.001]
  • [Cites] Development. 1991 Dec;113(4):1093-104 [1811929.001]
  • [Cites] Arch Surg. 1991 Dec;126(12):1514-9 [1842182.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Sep;20(1):93-7 [9290960.001]
  • [Cites] Dermatol Surg. 1997 Oct;23(10):929-33 [9357504.001]
  • [Cites] Am J Dermatopathol. 1999 Feb;21(1):16-20 [10027519.001]
  • [Cites] Histopathology. 1999 Feb;34(2):163-9 [10064396.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):153-8 [10067813.001]
  • [Cites] Arch Surg. 1999 Apr;134(4):388-92; discussion 392-3 [10199311.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2589-95 [10375107.001]
  • [Cites] Transplantation. 1999 Dec 15;68(11):1717-21 [10609948.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):58-62 [10665914.001]
  • [Cites] Dermatol Surg. 2000 Feb;26(2):138-41 [10691943.001]
  • [Cites] Plast Reconstr Surg. 2000 Feb;105(2):680-3 [10697177.001]
  • [Cites] J Cutan Pathol. 2000 Mar;27(3):118-20 [10728812.001]
  • [Cites] Br J Dermatol. 2000 Mar;142(3):525-8 [10735964.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2493-9 [10856110.001]
  • [Cites] Ultrastruct Pathol. 1983 Mar-Apr;4(2-3):219-25 [6349064.001]
  • [Cites] Pathologe. 1983 Nov;4(6):287-93 [6664956.001]
  • [Cites] Ann Pathol. 1983 Dec;3(4):285-91 [6667285.001]
  • [Cites] Histopathology. 1983 Mar;7(2):229-49 [6852784.001]
  • [Cites] Am J Dermatopathol. 1982 Dec;4(6):513-5 [7165060.001]
  • [Cites] Cancer. 1978 Nov;42(5):2311-21 [719609.001]
  • [Cites] Hum Pathol. 1980 Sep;11(5 Suppl):586-8 [7429511.001]
  • [Cites] J Comp Neurol. 1980 Nov 15;194(2):475-96 [7440811.001]
  • [Cites] J Invest Dermatol. 1995 Mar;104(3):411-6 [7532197.001]
  • [Cites] Mod Pathol. 1995 May;8(4):384-8 [7567935.001]
  • [Cites] Dermatol Surg. 1995 Aug;21(8):669-83 [7633811.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1401-7 [7635780.001]
  • [Cites] Plast Reconstr Surg. 1994 Dec;94(7):970-5 [7661915.001]
  • [Cites] Virchows Arch. 1995;426(3):317-21 [7773512.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):315-23 [7836085.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):325-31 [7836086.001]
  • [Cites] Rev Stomatol Chir Maxillofac. 1995;96(1):33-5 [7899811.001]
  • [Cites] J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):143-56 [8335732.001]
  • [Cites] Am J Clin Oncol. 1993 Feb;16(1):54-7 [8424405.001]
  • [Cites] J Am Acad Dermatol. 1993 Feb;28(2 Pt 1):222-6 [8432919.001]
  • [Cites] Cancer Genet Cytogenet. 1993 May;67(1):65-70 [8504402.001]
  • [Cites] Arch Histol Cytol. 1995 Oct;58(4):379-96 [8562130.001]
  • [Cites] Dermatol Surg. 1996 Mar;22(3):262-7 [8599738.001]
  • [Cites] Virchows Arch. 1996 Jul;428(4-5):305-9 [8764942.001]
  • [Cites] Prog Neurobiol. 1996 Jul;49(4):317-34 [8888113.001]
  • [Cites] Am Surg. 1996 Nov;62(11):879-82 [8895705.001]
  • [Cites] Arch Dermatol Res. 1996 Apr;288(4):184-7 [8967790.001]
  • [Cites] Am J Surg Pathol. 1997 Feb;21(2):226-34 [9042291.001]
  • [Cites] Am Surg. 1997 May;63(5):450-4 [9128236.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1997;9(3):164-7 [9269548.001]
  • [Cites] Dermatol Surg. 2000 Sep;26(9):853-6 [10971559.001]
  • [Cites] Arch Oral Biol. 2000 Oct;45(10):879-87 [10973561.001]
  • [Cites] J Invest Dermatol. 1975 Jul;65(1):71-84 [1097542.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1217-23 [10976695.001]
  • [Cites] J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):755-67 [11050578.001]
  • [Cites] Br J Dermatol. 2000 Oct;143(4):837-9 [11069467.001]
  • [Cites] J Dermatol Sci. 2000 Dec;24(3):203-11 [11084302.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2000 Nov;16(6):453-8 [11106191.001]
  • [Cites] Histopathology. 2000 Nov;37(5):445-51 [11119126.001]
  • [Cites] Arch Pathol Lab Med. 2001 Feb;125(2):228-31 [11175640.001]
  • [Cites] Am J Dermatopathol. 2001 Feb;23(1):16-23 [11176047.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Feb;127(2):149-54 [11177031.001]
  • [Cites] J Cutan Med Surg. 2000 Oct;4(4):186-95 [11231196.001]
  • [Cites] J Am Acad Dermatol. 2002 Apr;46(4):640-2 [11907528.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):4173-7 [11911314.001]
  • [Cites] Br J Dermatol. 2002 Apr;146(4):671-3 [11966703.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):352-60 [11992403.001]
  • [Cites] Transplant Proc. 2002 Aug;34(5):1780-1 [12176573.001]
  • [Cites] Plast Reconstr Surg. 2002 Oct;110(5):1259-65 [12360064.001]
  • [Cites] Head Neck. 2002 Nov;24(11):982-8 [12410532.001]
  • [Cites] J Am Acad Dermatol. 2002 Dec;47(6):885-92 [12451374.001]
  • [Cites] Br J Ophthalmol. 2003 Feb;87(2):240 [12543759.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 Jan;17(1):20-4 [12602962.001]
  • [Cites] Adv Anat Pathol. 2003 Mar;10(2):101-6 [12605092.001]
  • [Cites] Dev Biol. 2003 Jan 15;253(2):258-63 [12645929.001]
  • [Cites] J Dermatol Sci. 2003 May;31(3):219-24 [12727026.001]
  • [Cites] Anticancer Res. 2003 Jul-Aug;23(4):3379-96 [12926079.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):607-10 [12943628.001]
  • [Cites] Am J Pathol. 1992 Feb;140(2):427-47 [1371204.001]
  • [Cites] J Am Acad Dermatol. 2003 Nov;49(5):832-41 [14576661.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Dec;11(4):326-9 [14663358.001]
  • [Cites] Arch Dermatol. 2003 Dec;139(12):1587-90 [14676075.001]
  • [Cites] Mod Pathol. 2004 May;17(5):561-7 [15001998.001]
  • [Cites] Am J Surg Pathol. 1992 Jul;16(7):658-66 [1530107.001]
  • [Cites] Br J Dermatol. 1997 Oct;137(4):637-41 [9390346.001]
  • [Cites] Am J Surg. 1997 Dec;174(6):688-93 [9409598.001]
  • [Cites] Tumori. 1997 Sep-Oct;83(5):868-72 [9428924.001]
  • [Cites] CA Cancer J Clin. 1998 Jan-Feb;48(1):6-29 [9449931.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1503-8 [9537255.001]
  • [Cites] Am J Clin Pathol. 1998 May;109(5):565-70 [9576574.001]
  • [Cites] J Surg Oncol. 1998 Apr;67(4):251-4 [9579373.001]
  • [Cites] Am J Dermatopathol. 1998 Aug;20(4):346-51 [9700371.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Sep;23(1):67-71 [9713999.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1998 Aug;236(8):561-6 [9717649.001]
  • [Cites] Ann Surg. 1999 Jan;229(1):97-105 [9923806.001]
  • [Cites] Am J Clin Oncol. 2001 Feb;24(1):35-42 [11232947.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1358-62 [11283937.001]
  • [Cites] Ann Surg Oncol. 2001 Apr;8(3):204-8 [11314935.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2107-15 [11395388.001]
  • [Cites] J Am Acad Dermatol. 2001 Aug;45(2):303-8 [11464197.001]
  • [Cites] Mod Pathol. 2001 Sep;14(9):880-5 [11557784.001]
  • [Cites] Am Surg. 2001 Oct;67(10):943-7 [11603550.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1650-5 [11745244.001]
  • [Cites] Lancet. 2002 Feb 9;359(9305):497-8 [11853800.001]
  • [Cites] Dermatol Surg. 2002 Feb;28(2):113-7; discussion 117 [11860419.001]
  • [Cites] Aust N Z J Surg. 1988 Dec;58(12):971-4 [3202731.001]
  • [Cites] J Dermatol Surg Oncol. 1988 Jan;14(1):11-3 [3275699.001]
  • [Cites] Ann Surg. 1988 Feb;207(2):201-7 [3277546.001]
  • [Cites] Cancer. 1988 Aug 15;62(4):683-5 [3293760.001]
  • [Cites] Cancer. 1988 Jul 1;62(1):28-31 [3383119.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jun;14(6):1077-84 [3384714.001]
  • [Cites] J Invest Dermatol. 1986 Dec;87(6):779-87 [3782861.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):178-82 [3940617.001]
  • [Cites] Dev Biol. 1991 Apr;144(2):281-300 [2010033.001]
  • [Cites] Br J Surg. 1991 Feb;78(2):138-42 [2015460.001]
  • [Cites] J Am Acad Dermatol. 1990 Aug;23(2 Pt 1):254-6 [2170468.001]
  • [Cites] Plast Reconstr Surg. 1990 Aug;86(2):347-51 [2367585.001]
  • [Cites] Pathology. 1986 Oct;18(4):393-9 [2434904.001]
  • [Cites] Ultrastruct Pathol. 1986;10(6):473-95 [2435039.001]
  • [Cites] Acta Pathol Jpn. 1987 Feb;37(2):331-7 [2440231.001]
  • [Cites] Acta Derm Venereol. 1987;67(6):517-20 [2451378.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;58(2):95-121 [2575822.001]
  • [Cites] Am J Surg Pathol. 1985 Feb;9(2):109-16 [2579592.001]
  • [Cites] Am J Surg Pathol. 1985 Feb;9(2):95-108 [2579594.001]
  • [Cites] Lab Invest. 1985 Apr;52(4):334-53 [2580118.001]
  • [Cites] Arch Dermatol. 1989 Aug;125(8):1096-100 [2757407.001]
  • [Cites] Arch Pathol Lab Med. 1987 Sep;111(9):813-8 [2820344.001]
  • [Cites] Am J Surg Pathol. 1988 Nov;12(11):877-84 [2847571.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 May;83(10):3500-4 [3010302.001]
  • [Cites] Am J Pathol. 1987 Feb;126(2):243-57 [3103452.001]
  • [Cites] Mol Cell Probes. 1987 Dec;1(4):367-81 [3134611.001]
  • [Cites] Pathol Annu. 1984;19 Pt 2:1-30 [6209606.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):238-45 [6344978.001]
  • (PMID = 16466578.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1382229
  •  go-up   go-down


16. Veness MJ, Perera L, McCourt J, Shannon J, Hughes TM, Morgan GJ, Gebski V: Merkel cell carcinoma: improved outcome with adjuvant radiotherapy. ANZ J Surg; 2005 May;75(5):275-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma: improved outcome with adjuvant radiotherapy.
  • BACKGROUND: Merkel cell carcinoma is an aggressive primary cutaneous neuroendocrine carcinoma.
  • METHODS: Between 1980 and 2002, 86 patients diagnosed with Merkel cell carcinoma were treated with curative intent at Westmead Hospital, Sydney.
  • Disease-free survival and overall survival was calculated using Kaplan-Meier survival curves.
  • RESULTS: Median age at diagnosis was 75 years (range 46-89 years) in 49 men and 37 women.
  • Fifty-one (59%) patients presented with a primary lesion, 19 (22%) with a primary lesion and clinical nodal disease and 16 (19%) with lymph node metastases from an unknown primary.
  • Patients treated with surgery and adjuvant radiotherapy experienced a better median disease free survival compared to those undergoing surgery alone (10.5 months vs 4 months; P < 0.01).
  • The 5-year overall and disease-free survival rate for the entire study population was 47% and 25%, respectively.
  • Twenty-six patients (30%) died as a result of Merkel cell carcinoma.
  • CONCLUSION: Merkel cell carcinoma is an aggressive skin cancer.
  • [MeSH-major] Carcinoma, Merkel Cell / radiotherapy. Carcinoma, Merkel Cell / surgery. Radiotherapy, Adjuvant. Skin Neoplasms / radiotherapy. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Proportional Hazards Models. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15932436.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


17. Hersberger M, Thun GA, Imboden M, Brandstätter A, Waechter V, Summerer M, Schmid-Grendelmeier P, Bircher A, Rohrer L, Berger W, Russi EW, Rochat T, Kronenberg F, Probst-Hensch N: Association of STR polymorphisms in CMA1 and IL-4 with asthma and atopy: the SAPALDIA cohort. Hum Immunol; 2010 Nov;71(11):1154-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Asthma is a chronic pulmonary disorder that is characterized by airway inflammation and bronchial hyperreactivity.
  • In this study, we investigated the association of STR polymorphisms in genes encoding mast cell chymase (CMA1), uteroglobin (UGB), tumor necrosis factor-α (TNF-α) and interleukin-4 (IL-4) with asthma and atopic phenotypes in the large population-based Swiss Cohort Study SAPALDIA.
  • This minor IL-4 2-allele was also associated with higher IgE levels, with a higher risk for a positive skin prick test and with a trend for a higher risk for bronchial hyperresponsiveness.
  • [MeSH-major] Asthma / genetics. Asthma / immunology. Chymases / genetics. Interleukin-4 / genetics. Microsatellite Repeats / genetics
  • [MeSH-minor] Adolescent. Adult. Bronchial Hyperreactivity. Disease Progression. Female. Genetic Association Studies. Humans. Immunoglobulin E / blood. Male. Middle Aged. Skin Tests. Switzerland. Tumor Necrosis Factor-alpha / genetics. Uteroglobin / genetics

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20736038.001).
  • [ISSN] 1879-1166
  • [Journal-full-title] Human immunology
  • [ISO-abbreviation] Hum. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4; 37341-29-0 / Immunoglobulin E; 9060-09-7 / Uteroglobin; EC 3.4.21.39 / CMA1 protein, human; EC 3.4.21.39 / Chymases
  •  go-up   go-down


18. Nolan RC, Chan MT, Heenan PJ: A clinicopathologic review of lethal nonmelanoma skin cancers in Western Australia. J Am Acad Dermatol; 2005 Jan;52(1):101-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathologic review of lethal nonmelanoma skin cancers in Western Australia.
  • BACKGROUND: Nonmelanoma skin cancer (NMSC) comprises a heterogeneous group of cancers.
  • OBJECTIVE: We sought to document the population affected by lethal NMSC, the types of tumors involved, and their histopathologic features.
  • Histology of the primary lesion was reviewed in cases when the primary lesion was identified and sections were available.
  • RESULTS: A total of 120 NMSC deaths occurred, including 89 caused by squamous cell carcinoma, 22 by Merkel cell carcinoma, and 9 others.
  • When the primary lesion was identified (n = 45), the median survival after diagnosis was 17 months; 75% of patients died within 3 years.
  • Three squamous cell carcinomas were reclassified as adenosquamous carcinoma.
  • [MeSH-major] Skin Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Merkel Cell / mortality. Carcinoma, Merkel Cell / pathology. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Registries. Survival Analysis. Western Australia / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15627087.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Dim DC, Nugent SL, Darwin P, Peng HQ: Metastatic merkel cell carcinoma of the pancreas mimicking primary pancreatic endocrine tumor diagnosed by endoscopic ultrasound-guided fine needle aspiration cytology: a case report. Acta Cytol; 2009 Mar-Apr;53(2):223-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic merkel cell carcinoma of the pancreas mimicking primary pancreatic endocrine tumor diagnosed by endoscopic ultrasound-guided fine needle aspiration cytology: a case report.
  • BACKGROUND: Merkel cell carcinoma (MCC) is a relatively infrequent, rapidly progressive and often fatal cutaneous malignancy exhibiting neuroendocrine differentiation.
  • It has a penchant for local recurrence and distant metastasis to various sites, including regional lymph nodes, distant skin, lung, liver, testis and other rare organs, such as the pancreas.
  • There are only 4 cases of MCC metastatic to the pancreas reported in the English-language literature, and they were all diagnosed by histology from pancreatic resection.
  • She had a history of MCC of the upper extremity with wide local excision 15 months earlier.
  • Metastatic MCC was diagnosed based on the cytomorphology, characteristic immunohistochemical staining pattern, clinical history and comparison of the morphology with that of the primary tumor.
  • CONCLUSION: The cytomorphology and immunohistochemical profile of this neoplasm mimicked a pancreatic endocrine tumor.
  • We discuss the diagnostic pitfalls and differential diagnoses of the metastatic pancreatic MCC, highlighting the importance of thorough clinical history, attention to cytologic detail and corroborating immunohirtochemistry in arriving at the correct diagns.
  • This is the first case ofa metastatic pancreatic MCC diagnosed by EUS-FNA cytology.
  • [MeSH-major] Carcinoma, Merkel Cell / secondary. Endocrine Gland Neoplasms / pathology. Pancreatic Neoplasms / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Endosonography. Female. Humans. Immunohistochemistry. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365981.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Henness S, Vereecken P: Management of Merkel tumours: an evidence-based review. Curr Opin Oncol; 2008 May;20(3):280-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of Merkel tumours: an evidence-based review.
  • (1) Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer of neuroendocrine origin generally seen in patients over 50 years of age.
  • It has a high propensity for recurrence post-treatment; 5-year overall survival rates range from 23% to 80%. (2) The rarity of MCC means that there is a lack of prospective controlled trials in these patients.
  • Patients are generally treated with surgery as a first-line therapy, supplemented with adjuvant radiotherapy and chemotherapy if required. (3) The use of adjuvant therapies in MCC remains controversial.
  • Data from case series and meta-analyses of case series suggest that the addition of radiotherapy to surgery in patients with MCC can confer significant benefits with regard to reducing local and regional recurrence rates and prolonging disease-free survival.
  • Generally, the current literature tends not to support the use of chemotherapy in these patients. (4) Stage-specific treatment regimens have been outlined involving various combinations of surgery, radiation and chemotherapy for International Union Against Cancer (UICC) stage I to III disease, while the emphasis of treatment in patients with UICC stage IV disease is on palliative care with or without radio- or chemotherapy.
  • There is a need for more structured clinical research to better illuminate the most effective treatments for this disease.
  • [MeSH-major] Carcinoma, Merkel Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18391627.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


21. Batlle M, Pérez-Villa F, Lázaro A, Garcia-Pras E, Ramirez J, Ortiz J, Orús J, Roqué M, Heras M, Roig E: Correlation between mast cell density and myocardial fibrosis in congestive heart failure patients. Transplant Proc; 2007 Sep;39(7):2347-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between mast cell density and myocardial fibrosis in congestive heart failure patients.
  • Besides the well-established role of mast cells in allergic reactions as an important source of vasoactive and proinflammatory products, they have been related to tissue fibrosis and remodelling processes.
  • In a heart failure (HF) animal model, mast cells were shown to synthesize transforming growth factor beta1 and basic fibroblast growth factor in myocardial tissue and were localized to an area with fibrosis.
  • Our objective was to quantify mast cell density in left ventricles from patients with congestive heart failure who were candidates for transplantation and to analyze whether they showed a correlation with the fibrosis level of the same area.
  • Mast cells were detected by immunohistochemistry with a human mast cell chymase antibody and fibrosis levels measured with picrosirius red staining of collagen fibrils with later quantification by morphometry.
  • Mast cell density correlated with the collagen fraction and could be fitted to a linear regression curve: collagen fraction = 0.78 + 0.05 mast cell density (n = 33, P < .005, R2 = 0.28).
  • Due to the mast cells capacity to synthesize vasoactive and fibrogenic products and the correlation between their density and fibrosis levels, they probably play a role in the ventricular remodelling in HF.
  • [MeSH-major] Collagen / metabolism. Heart Failure / pathology. Heart Failure / surgery. Heart Transplantation / pathology. Mast Cells / pathology. Myocardium / pathology


22. Sandel HD 4th, Day T, Richardson MS, Scarlett M, Gutman KA: Merkel cell carcinoma: does tumor size or depth of invasion correlate with recurrence, metastasis, or patient survival? Laryngoscope; 2006 May;116(5):791-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma: does tumor size or depth of invasion correlate with recurrence, metastasis, or patient survival?
  • OBJECTIVE: The objective of this retrospective study and literature review was to compare the clinical and histologic criteria including tumor size and depth of invasion with outcomes in patients with Merkel cell carcinoma.
  • METHODS: The state cancer registry provided patients (n = 46) diagnosed with Merkel cell carcinoma from 1992 through 2002.
  • Pathology slides were reviewed by the author for tumor size, depth of invasion, Clark level, and margin status.
  • Patients were excluded from specific analysis based on misdiagnosis, unavailability of pathology slides, absent medical records, or those lost to follow up.
  • RESULTS: Disease-free survival rates were 52%, 39%, and 9% at 1, 2, and 5 years, respectively.
  • The average disease-free interval was 18.4 months (range, 1-80 months).
  • No correlation was found between tumor size (P = .49), depth (P = .41), or Clark level (P = .82) to overall survival.
  • A trend was found comparing tumor size or depth of invasion with local recurrence (P = .07) but with no correlation to regional recurrence (P = .93 and P = .60) or distant metastasis (P = .16 and P = .24).
  • CONCLUSIONS: No correlation was found between tumor size or depth of invasion to patient survival or metastasis.
  • However, there was a trend toward increased local and regional recurrence rates when comparing size and depth and in specimens with positive tumor margins.
  • These outcomes are consistent with those reported in recent literature and further characterize the unpredictable nature of this disease.
  • An aggressive approach should be taken, including wide local excision with negative tumor margins and lymph node dissection; however, larger multistate reviews are needed for additional support.
  • [MeSH-major] Carcinoma, Merkel Cell / mortality. Carcinoma, Merkel Cell / pathology. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / mortality. Skin Neoplasms / mortality. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16652089.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Daghistani W, Younan R, Brutus JP: Merkel cell carcinoma of the hand: case report and literature review. Chir Main; 2010 Apr;29(2):128-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma of the hand: case report and literature review.
  • We are reporting on a 72-year-old male who was diagnosed with Merkel cell carcinoma on the dorsal aspect of his left index finger.
  • This rare highly aggressive malignancy of the skin has only exceptionally been described on the finger or hand.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / surgery. Fingers. Skin Neoplasms / diagnosis. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Amputation. Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Rare Diseases. Risk Factors. Sentinel Lymph Node Biopsy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20202882.001).
  • [ISSN] 1769-6666
  • [Journal-full-title] Chirurgie de la main
  • [ISO-abbreviation] Chir Main
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 16
  •  go-up   go-down


24. Stone BL, Boehme S, Mundorff MB, Maloney CG, Srivastava R: Hospital admission medication reconciliation in medically complex children: an observational study. Arch Dis Child; 2010 Apr;95(4):250-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate admission medication reconciliation in children with medically complex conditions (MCC) by determining the availability and accuracy of five information sources and characterising admitting order errors.
  • PARTICIPANTS: 23 children with MCC identified from 219 admissions between 16 December 2004 and 7 January 2005.
  • RESULTS: Children with MCC averaged 5.3 chronic medications.
  • Availability/sensitivity/specificity respectively were parents 52%/0.75/0.96, pharmacy 61%/0.64/0.74, primary provider 43%/0.25/0.86, last admission electronic health record 87%/0.74/0.33 and admitting history 65%/0.31/0.94.
  • CONCLUSIONS: In children with MCC admitted at our institution during the study period, no medication information source was optimally available, sensitive and specific.
  • [MeSH-major] Chronic Disease / drug therapy. Hospitals, Pediatric / organization & administration. Medication Errors / prevention & control. Medication Systems, Hospital / organization & administration. Patient Admission / standards
  • [MeSH-minor] Child. Continuity of Patient Care / organization & administration. Continuity of Patient Care / standards. Epidemiologic Methods. Humans. Medical History Taking / standards. Medical Records / standards. Utah

  • MedlinePlus Health Information. consumer health - Coping with Chronic Illness.
  • MedlinePlus Health Information. consumer health - Medication Errors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19948664.001).
  • [ISSN] 1468-2044
  • [Journal-full-title] Archives of disease in childhood
  • [ISO-abbreviation] Arch. Dis. Child.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K23 HD052553
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


25. Requena L, Jaqueti G, Rütten A, Mentzel T, Kutzner H: Merkel cell carcinoma within follicular cysts: report of two cases. J Cutan Pathol; 2008 Dec;35(12):1127-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma within follicular cysts: report of two cases.
  • Merkel cell carcinoma is a rare cutaneous neoplasm of unknown histogenesis.
  • Several reports have described the association of Merkel cell carcinoma of the skin with other cutaneous neoplasms within the same lesion, and there are also reports describing three examples of Merkel cell carcinoma within follicular cysts.
  • We describe two examples of Merkel cell carcinoma developed within epithelial cysts.
  • Neoplastic cells of Merkel cell tumor expressed immunoreactivity for chromogranin, synaptophysin, neuron-specific enolase, CAM 5.2 and cytokeratin 20, the last two markers showing the characteristic paranuclear dot-like pattern.
  • In contrast, the epithelial wall lining the cyst and surrounding Merkel cell tumor only expressed immunoreactivity for cytokeratin MNF116.
  • The description of five cases of Merkel cell carcinoma within follicular cysts, including the two cases of this report, support some relationship between Merkel cell tumor and the hair follicle.
  • [MeSH-major] Carcinoma, Merkel Cell / complications. Carcinoma, Merkel Cell / pathology. Follicular Cyst / complications. Follicular Cyst / pathology. Skin Neoplasms / complications. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18988316.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


26. Kurnatowska I, Zawiasa A, Narbutt J, Wagrowska-Danielewicz M, Stempien M, Nowicki M: Merkel cell carcinoma in a kidney transplant patient: Case report and update on management. Ann Transplant; 2010 Jul-Sep;15(3):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma in a kidney transplant patient: Case report and update on management.
  • BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine tumor.
  • MCC is found almost exclusively on sun-exposed facial sites.
  • CASE REPORT: We describe a case of a 62-year-old male renal transplant recipient who was diagnosed with MCC with primary atypical localization on the buttock 5 years after transplantation.
  • Despite the conversion from CsA to mTOR inhibitor, surgical operation, and radiotherapy, the patient developed disseminated skin lesions and died due to multiple metastases.
  • CONCLUSIONS: This case emphasizes the importance of screening for MCC in atypical localizations in transplant organ recipients.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Kidney Transplantation / adverse effects. Skin Neoplasms / diagnosis


27. Quante M, Hille S, Schofer MD, Lorenz J, Hauck M: Noxious counterirritation in patients with advanced osteoarthritis of the knee reduces MCC but not SII pain generators: A combined use of MEG and EEG. J Pain Res; 2008;1:1-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noxious counterirritation in patients with advanced osteoarthritis of the knee reduces MCC but not SII pain generators: A combined use of MEG and EEG.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 1999 Mar 15;19(6):2394-400 [10066289.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 1984 Jul;6(7):405-10 [6503475.001]
  • [Cites] Electroencephalogr Clin Neurophysiol Suppl. 1999;49:245-9 [10533118.001]
  • [Cites] Brain Res. 2000 Apr 17;862(1-2):103-10 [10799674.001]
  • [Cites] J Clin Neurophysiol. 2000 May;17(3):295-308 [10928641.001]
  • [Cites] Eur J Pain. 2000;4(3):229-38 [10985866.001]
  • [Cites] Pain. 2000 Oct;88(1):69-78 [11098101.001]
  • [Cites] Prog Brain Res. 2000;129:289-302 [11098697.001]
  • [Cites] Prog Brain Res. 2000;129:313-22 [11098699.001]
  • [Cites] Pain. 2001 Apr;91(3):287-96 [11275386.001]
  • [Cites] News Physiol Sci. 2001 Oct;16:244-9 [11572930.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Feb;300(2):513-20 [11805211.001]
  • [Cites] Eur J Pain. 2002;6(2):149-59 [11900475.001]
  • [Cites] Eur J Pain. 2002;6(2):161-76 [11900476.001]
  • [Cites] J Neurosci. 2002 Apr 15;22(8):3206-14 [11943821.001]
  • [Cites] Pain. 2003 Jan;101(1-2):155-65 [12507710.001]
  • [Cites] Pain. 2003 Jan;101(1-2):167-74 [12507711.001]
  • [Cites] J Rehabil Med. 2003 May;(41 Suppl):66-72 [12817660.001]
  • [Cites] Pain. 1992 Aug;50(2):177-87 [1408314.001]
  • [Cites] Neurophysiol Clin. 2003 Dec;33(6):293-301 [14678843.001]
  • [Cites] Rheumatology (Oxford). 2005 Jan;44(1):7-16 [15292527.001]
  • [Cites] Ann Rheum Dis. 2005 Sep;64(9):1263-7 [15731292.001]
  • [Cites] Nat Rev Neurosci. 2005 Jul;6(7):533-44 [15995724.001]
  • [Cites] Ann Neurol. 1978 Nov;4(5):451-62 [216303.001]
  • [Cites] Pain. 1987 Aug;30(2):221-32 [3670874.001]
  • [Cites] Psychiatry Res. 1985 Apr;14(4):343-51 [3860887.001]
  • [Cites] Brain Res. 1984 Oct 29;321(1):165-8 [6149790.001]
  • [Cites] Brain Res. 1982 Nov 11;251(1):83-92 [6293648.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10413-20 [8248123.001]
  • [Cites] Eur J Neurosci. 2001 Jan;13(2):230-40 [11168527.001]
  • [Cites] J Neurophysiol. 2001 Sep;86(3):1499-503 [11535693.001]
  • [Cites] Ann N Y Acad Sci. 2001 Mar;933:157-74 [12000018.001]
  • [Cites] Pain. 2002 Nov;100(1-2):1-6 [12435453.001]
  • [Cites] Pain. 2003 Apr;102(3):265-71 [12670668.001]
  • [Cites] Pain. 2004 Jul;110(1-2):72-8 [15275754.001]
  • [Cites] Pain. 2005 Aug;116(3):359-65 [15979791.001]
  • [Cites] Suppl Clin Neurophysiol. 2004;57:3-7 [16106600.001]
  • [Cites] Eur J Pain. 2006 Nov;10(8):757-65 [16439173.001]
  • [Cites] Clin J Pain. 2007 Jul-Aug;23(6):506-10 [17575490.001]
  • [Cites] J Neurophysiol. 1996 Nov;76(5):3025-37 [8930252.001]
  • [Cites] Brain Res. 1998 Aug 10;801(1-2):206-10 [9729389.001]
  • [Cites] Eur J Neurosci. 1998 Jul;10(7):2476-80 [9749775.001]
  • [Cites] Electroencephalogr Clin Neurophysiol. 1998 Oct;107(4):227-53 [9872441.001]
  • [Cites] J Neurophysiol. 1991 Sep;66(3):1021-32 [1753273.001]
  • [Cites] Pain. 1988 Sep;34(3):245-52 [3186271.001]
  • [Cites] Pain. 1979 Jun;6(3):283-304 [460935.001]
  • [Cites] Pain. 1979 Jun;6(3):305-27 [460936.001]
  • [Cites] Brain. 1984 Mar;107 ( Pt 1):107-14 [6320949.001]
  • [Cites] Pain. 1999 Feb;79(2-3):105-11 [10068155.001]
  • (PMID = 21197282.001).
  • [ISSN] 1178-7090
  • [Journal-full-title] Journal of pain research
  • [ISO-abbreviation] J Pain Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3004616
  • [Keywords] NOTNLM ; DNIC / EEG / MEG / chronic pain / counterirritation / osteoarthritis
  •  go-up   go-down


28. Shaw M, Warren S, Groben P, Gulley ML: No evidence of Epstein-Barr virus association with Merkel cell carcinoma. J Cutan Pathol; 2006 Sep;33(9):624-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No evidence of Epstein-Barr virus association with Merkel cell carcinoma.
  • BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive tumor of cutaneous neuroendocrine cells with a reported 13-fold increased incidence in immunocompromised patients, raising the possibility that it is driven by an oncogenic virus.
  • Additionally, Merkel cell hyperplasia is seen in the Epstein-Barr virus (EBV)-driven process oral hairy leukoplakia, and EBV is known to be involved in the pathogenesis of several other malignancies.
  • OBJECTIVE: We tested the hypothesis that EBV is involved in MCC.
  • METHODS: We employed EBV-encoded RNA in situ hybridization (ISH), lytic EBV ISH, latent membrane protein 1 immunohistochemistry, and BamH1Z leftward reading frame 1 immunohistochemistry to detect and localize EBV in paraffin sections of MCC from five patients as well as seven other cutaneous tumors and positive controls for EBV infection.
  • However, there was no evidence of latent or lytic EBV in any of the MCC biopsies or other cutaneous tumors.
  • CONCLUSION: Our findings suggest that EBV is not associated with MCC.
  • [MeSH-major] Carcinoma, Merkel Cell / virology. Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / isolation & purification. Skin Neoplasms / virology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. RNA, Viral / isolation & purification

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2006.
  • (PMID = 16965337.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK08386
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


29. Jiang L, Li M, Wen Z, Wang K, Diao Y: Prediction of mitochondrial proteins using discrete wavelet transform. Protein J; 2006 Jun;25(4):241-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The system can predict these sequences with sensitivity, specificity, accuracy and MCC of 50.30%, 95.74%, 76.53% and 0.54, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proteins. 1998 Jan;30(1):49-60 [9443340.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W414-9 [15215421.001]
  • [Cites] Genome Inform Ser Workshop Genome Inform. 1997;8:53-60 [11072305.001]
  • [Cites] Genome Inform. 2001;12:103-12 [11791229.001]
  • [Cites] Bioinformatics. 2004 Nov 1;20(16):2572-8 [15117757.001]
  • [Cites] Bioinformatics. 2004 Jul 22;20(11):1785-94 [15037509.001]
  • [Cites] Protein Eng. 2002 Mar;15(3):193-203 [11932490.001]
  • [Cites] Eur J Biochem. 1996 Nov 1;241(3):779-86 [8944766.001]
  • [Cites] Comput Appl Biosci. 1995 Aug;11(4):441-7 [8521054.001]
  • [Cites] J Biol Chem. 2005 Apr 15;280(15):14427-32 [15647269.001]
  • [Cites] J Mol Biol. 2000 Jul 21;300(4):1005-16 [10891285.001]
  • [Cites] Nucleic Acids Res. 2000 Jan 1;28(1):374 [10592278.001]
  • [Cites] Protein Eng. 1999 Feb;12(2):107-18 [10195282.001]
  • [Cites] In Silico Biol. 2004;4(2):133-48 [15107019.001]
  • [Cites] Bioinformatics. 2003 Jan;19(1):2-9 [12499286.001]
  • [Cites] Proteomics. 2004 Jun;4(6):1581-90 [15174128.001]
  • [Cites] Nucleic Acids Res. 2000 Jan 1;28(1):155-8 [10592209.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D459-62 [14681457.001]
  • [Cites] Bioinformatics. 2001 Aug;17(8):721-8 [11524373.001]
  • [Cites] Nucleic Acids Res. 2000 Jan 1;28(1):45-8 [10592178.001]
  • [Cites] Protein Eng. 2002 Sep;15(9):713-5 [12456868.001]
  • [Cites] In Silico Biol. 2002;2(3):291-303 [12542414.001]
  • [Cites] Biochim Biophys Acta. 1975 Oct 20;405(2):442-51 [1180967.001]
  • [Cites] Comput Biol Chem. 2005 Jun;29(3):220-8 [15979042.001]
  • [Cites] Acc Chem Res. 2003 Apr;36(4):276-83 [12693925.001]
  • [Cites] Genomics. 1992 Dec;14(4):897-911 [1478671.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):45765-9 [12186861.001]
  • [Cites] Nat Genet. 1998 Jul;19(3):214-5 [9662387.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]
  • [Cites] Trends Biochem Sci. 1999 Jan;24(1):34-6 [10087920.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1995;30(4):275-349 [7587280.001]
  • [Cites] Nucleic Acids Res. 1998 May 1;26(9):2230-6 [9547285.001]
  • [Cites] Science. 1974 Sep 6;185(4154):862-4 [4843792.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):365-70 [12520024.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 19;278(2):477-83 [11097861.001]
  • (PMID = 16703470.001).
  • [ISSN] 1572-3887
  • [Journal-full-title] The protein journal
  • [ISO-abbreviation] Protein J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Mitochondrial Proteins
  •  go-up   go-down


30. Beer TW, Ng LB, Murray K: Mast cells have prognostic value in Merkel cell carcinoma. Am J Dermatopathol; 2008 Feb;30(1):27-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cells have prognostic value in Merkel cell carcinoma.
  • We examined the role of mast cell infiltrates and other clinical and histological factors in the prognosis of Merkel cell carcinoma.
  • Mast cells were stained immunohistochemically in 36 Merkel cell carcinomas with an antibody to tryptase.
  • The number of stainable cells was quantified within the tumors and surrounding stroma.
  • Patient prognosis was worse with higher tumor mast cell numbers (P < 0.002).
  • Prognosis was also found to be adversely affected by the presence of lymphovascular invasion (P = 0.03) and increased tumor size (P = 0.05).
  • Increased mast cells counts, tumor size, and lymphovascular invasion are associated with an adverse prognosis in Merkel cell carcinomas.
  • Evaluation of mast cell infiltrates may provide useful prognostic data and ultimately could assist in selecting patients that require adjuvant treatment in this aggressive form of skin cancer.
  • [MeSH-major] Carcinoma, Merkel Cell / immunology. Carcinoma, Merkel Cell / pathology. Mast Cells / immunology. Skin Neoplasms / immunology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Count. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212540.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Huang Y, Jia X, Zhu J, Chen B, Chen H, Liu Q: [Correlation of powder properties and formability of traditional Chinese medicine pellets]. Zhongguo Zhong Yao Za Zhi; 2010 Dec;35(23):3136-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: The present effort was designed to evaluate the effects of the characters of powder on pellets formation by extrusion-spheronization, taking Danggui Buxue decoction extracts as a model drug and microcrystalline cellulose (MCC) as an ideal balling material for extrusion-spheronization.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21355233.001).
  • [ISSN] 1001-5302
  • [Journal-full-title] Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
  • [ISO-abbreviation] Zhongguo Zhong Yao Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Powders
  •  go-up   go-down


32. Laity PR, Cameron RE: Synchrotron X-ray microtomographic study of tablet swelling. Eur J Pharm Biopharm; 2010 Jun;75(2):263-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specimens were prepared using combinations of hydroxypropyl-methyl-cellulose (HPMC) and microcrystalline cellulose (MCC) or pre-gelatinised starch (PGS), three materials commonly used as excipients for compacted tablets.
  • In particular, a sudden change was observed from gel-forming behaviour of formulations containing PGS or high HPMC content, to more rapid expansion and disintegration for formulations above 70% MCC.
  • This was most pronounced for the 10/90 HPMC/MCC specimens, which rapidly increased in thickness, while the diameter remained almost unchanged.
  • Although, in most cases, these bubbles were too small to be resolved (<60 microm), larger bubbles (diameter up to 1mm) were clearly evident in the rapidly swelling 10/90 HPMC/MCC specimens.

  • Hazardous Substances Data Bank. METHYL CELLULOSE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20172028.001).
  • [ISSN] 1873-3441
  • [Journal-full-title] European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V
  • [ISO-abbreviation] Eur J Pharm Biopharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Excipients; 0 / Gels; 0 / Tablets; 0 / microcrystalline cellulose; 3NXW29V3WO / Hypromellose Derivatives; 9004-34-6 / Cellulose; 9004-67-5 / Methylcellulose; 9005-25-8 / Starch
  •  go-up   go-down


33. Kanter RK, Cooper A: Mass critical care: pediatric considerations in extending and rationing care in public health emergencies. Disaster Med Public Health Prep; 2009 Dec;3 Suppl 2:S166-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article applies developing concepts of mass critical care (MCC) to children.
  • In public health emergencies (PHEs), MCC would improve population outcomes by providing lifesaving interventions while delaying less urgent care.
  • If needs exceed resources despite MCC, then rationing would allocate interventions to those most likely to survive with care.
  • Limitations will be encountered using adult ventilators for infants.
  • To ration MCC to children most likely to survive, the Pediatric Index of Mortality 2 score meets the criteria for validated pediatric mortality predictions.

  • MedlinePlus Health Information. consumer health - Critical Care.
  • MedlinePlus Health Information. consumer health - Disaster Preparation and Recovery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19794308.001).
  • [ISSN] 1938-744X
  • [Journal-full-title] Disaster medicine and public health preparedness
  • [ISO-abbreviation] Disaster Med Public Health Prep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Lovell P, Moroz LL: The largest growth cones in the animal kingdom: an illustrated guide to the dynamics of Aplysia neuronal growth in cell culture. Integr Comp Biol; 2006 Dec;46(6):847-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The largest growth cones in the animal kingdom: an illustrated guide to the dynamics of Aplysia neuronal growth in cell culture.
  • Simple networks can be reconstructed in cell culture and have been widely useful for cellular and molecular biological studies of neuronal growth, synaptogenesis, and learning and memory mechanisms.
  • Second, using time-lapse video microscopy we have characterized the dynamics of neuronal outgrowth for 3 identified cell types (mechanosensory neurons, L7 motoneurons, and modulatory MCC neurons) representing 3 major functional classes of neurons.
  • We show both cell-specific and neurite-specific growth characteristics and an irregular oscillatory rate of outgrowth ranging from 20 to 100 μm/h.
  • Finally, our observations can provide an illustrated guide to complex behavior of neurons and glia in cell culture as well as their dependence upon various trophic factors and responses to neuronal injury.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21672790.001).
  • [ISSN] 1540-7063
  • [Journal-full-title] Integrative and comparative biology
  • [ISO-abbreviation] Integr. Comp. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


35. Seili-Bekafigo I, Jonjić N, Stemberger C, Rajković-Molek K: Additional cytomorphological criteria in diagnosis of pilomatricoma--benign tumor with bad reputation. Coll Antropol; 2010 Mar;34(1):117-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional cytomorphological criteria in diagnosis of pilomatricoma--benign tumor with bad reputation.
  • Pilomatricomas (PM) are benign skin appendageal tumors, with differentiation towards hair-forming cells, usually found in children.
  • PM are often mistaken for "small round blue cell" tumors in children, or for Merkel cell carcinoma, basalioma and metastatic small cell carcinoma in adults, with possible over-aggressive therapeutic approach.
  • Clinical, cytomorphologic and basic morphometric features were analyzed, and compared with 4 cases of malignant tumors with similar clinical presentation.
  • We concluded that cytomorphologic characteristics of PM are reliable enough for correct preoperative diagnosis in adequate specimens, however the best results are achieved when FNA is performed by an experienced cytologist, and when all relevant clinical data are obtained.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Neoplasms / pathology. Pilomatrixoma / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Carcinoma, Basal Cell / pathology. Carcinoma, Merkel Cell / pathology. Child. Diagnosis, Differential. Eosine Yellowish-(YS). Epithelial Cells / pathology. Female. Humans. Male. Methylene Blue. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432739.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / May-Grunwald Giemsa; T42P99266K / Methylene Blue; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


41. Jia J, Yang L, Zhang ZZ: EHPred: an SVM-based method for epoxide hydrolases recognition and classification. J Zhejiang Univ Sci B; 2006 Jan;7(1):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A two-layer method based on support vector machines (SVMs) has been developed to distinguish epoxide hydrolases (EHs) from other enzymes and to classify its subfamilies using its primary protein sequences.
  • SVM classifiers were built using three different feature vectors extracted from the primary sequence of EHs: the amino acid composition (AAC), the dipeptide composition (DPC), and the pseudo-amino acid composition (PAAC).
  • Validated by 5-fold cross tests, the first layer SVM classifier can differentiate EHs and non-EHs with an accuracy of 94.2% and has a Matthew's correlation coefficient (MCC) of 0.84.
  • Using 2-fold cross validation, PAAC-based second layer SVM can further classify EH subfamilies with an overall accuracy of 90.7% and MCC of 0.87 as compared to AAC (80.0%) and DPC (84.9%).
  • A program called EHPred has also been developed to assist readers to recognize EHs and to classify their subfamilies using primary protein sequences with greater accuracy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Structure. 2000 Feb 15;8(2):111-22 [10673439.001]
  • [Cites] Bioinformatics. 2000 May;16(5):412-24 [10871264.001]
  • [Cites] Nucleic Acids Res. 1998 May 1;26(9):2230-6 [9547285.001]
  • [Cites] Nucleic Acids Res. 1994 Sep;22(17):3616-9 [7937069.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] CRC Crit Rev Biochem. 1987;22(1):39-88 [3115676.001]
  • [Cites] Bioinformatics. 2005 Jan 1;21(1):10-9 [15308540.001]
  • [Cites] Bioinformatics. 2004 Nov 1;20(16):2845-7 [15117755.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10637-42 [10485878.001]
  • [Cites] J Biol Chem. 1999 May 21;274(21):14579-86 [10329649.001]
  • [Cites] J Mol Biol. 2000 Jul 21;300(4):1005-16 [10891285.001]
  • [Cites] Chem Biol Interact. 2000 Dec 1;129(1-2):41-59 [11154734.001]
  • [Cites] Bioinformatics. 2001 Aug;17(8):721-8 [11524373.001]
  • [Cites] Bioinformatics. 2002 Jan;18(1):147-59 [11836223.001]
  • [Cites] Bioinformatics. 2002 May;18(5):689-96 [12050065.001]
  • [Cites] Biochemistry (Mosc). 2002 Oct;67(10):1099-108 [12460108.001]
  • [Cites] Proteins. 2003 Feb 1;50(2):290-302 [12486723.001]
  • [Cites] Math Biosci. 2003 Oct;185(2):111-22 [12941532.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D431-3 [14681450.001]
  • [Cites] Bioinformatics. 2004 Mar 1;20(4):586-7 [14990457.001]
  • [Cites] Proteins. 2004 Apr 1;55(1):66-76 [14997540.001]
  • [Cites] Proteins. 2004 Jun 1;55(4):846-55 [15146483.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W383-9 [15215416.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W414-9 [15215421.001]
  • [Cites] Biochim Biophys Acta. 1975 Oct 20;405(2):442-51 [1180967.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Jun;78(6):3824-8 [6167991.001]
  • [Cites] J Mol Biol. 1982 May 5;157(1):105-32 [7108955.001]
  • (PMID = 16365918.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 3.3.2.- / Epoxide Hydrolases
  • [Other-IDs] NLM/ PMC1361752
  •  go-up   go-down


42. Ramachary DB, Ramakumar K, Bharanishashank A, Narayana VV: Sequential one-pot combination of multireactions through multicatalysis: a general approach to rapid assembly of functionalized push-pull olefins, phenols, and 2-methyl-2H-chromenes. J Comb Chem; 2010 Nov 8;12(6):855-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A general, sustainable and practical process for the sequential cascade one-pot synthesis of library of highly substituted push-pull olefins, phenols and 2-methyl-2H-chromenes was reported through multicatalysis cascade (MCC) reactions.
  • Evidence for a new reaction pathway involving in situ formation of novel push-pull dienamines under amine- or amino acid-catalysis is presented along with examples demonstrating the amenability of the process to MCC chemistry.
  • [MeSH-major] Alkenes / chemistry. Benzopyrans / chemistry. Phenols / chemistry. Small Molecule Libraries / chemical synthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20858004.001).
  • [ISSN] 1520-4774
  • [Journal-full-title] Journal of combinatorial chemistry
  • [ISO-abbreviation] J Comb Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5,7-dimethoxy-2-methyl-2H-benzopyran; 0 / Alkenes; 0 / Benzopyrans; 0 / Phenols; 0 / Small Molecule Libraries
  •  go-up   go-down


43. Yom SS, Rosenthal DI, El-Naggar AK, Kies MS, Hessel AC: Merkel cell carcinoma of the tongue and head and neck oral mucosal sites. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Jun;101(6):761-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma of the tongue and head and neck oral mucosal sites.
  • Merkel cell carcinoma (MCC) is an uncommon primarily dermal malignancy of relatively aggressive biologic course.
  • We review this recent experience and present the first reported primary lingual MCC in a 57-year-old caucasian man.
  • We provide a review of oral mucosal MCC and guidelines for histopathologic and immunohistochemical diagnosis.
  • Merkel cell carcinoma should be included in the differential diagnosis of head and neck mucosal lesions, especially if the tumor is submucosal, and MCC may involve the tongue.
  • Mucosal MCC is aggressive, and there is a high risk for local recurrence and regional and distant metastasis.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Head and Neck Neoplasms / pathology. Tongue Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731397.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CAM 5.2 antigen; 0 / Chromogranin A; 0 / Chromogranins; 0 / KRT20 protein, human; 0 / Keratin-20; 0 / Synaptophysin; 68238-35-7 / Keratins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Number-of-references] 46
  •  go-up   go-down


44. Covas DT, de Oliveira FS, Rodrigues ES, Abe-Sandes K, Silva WA Jr, Fontes AM: Knops blood group haplotypes among distinct Brazilian populations. Transfusion; 2007 Jan;47(1):147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The African group presented a higher frequency of alleles McC(b), Sl2, and KAM+.
  • The haplotypes 1 (4646A, Kn(a), McC(a), Sl1, Sl4, KAM+), 2 (4646A, Kn(a), McC(a), Sl1, KAM-), and 3 (4646A, Kn(a), McC(a), Sl2, Sl4, KAM-) are the most frequent in all populations.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-SERINE .
  • Hazardous Substances Data Bank. ASPARAGINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207243.001).
  • [ISSN] 0041-1132
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Group Antigens; 0 / Receptors, Complement; 452VLY9402 / Serine; 7006-34-0 / Asparagine
  •  go-up   go-down


45. Shnayder Y, Weed DT, Arnold DJ, Gomez-Fernandez C, Bared A, Goodwin WJ, Civantos FJ: Management of the neck in Merkel cell carcinoma of the head and neck: University of Miami experience. Head Neck; 2008 Dec;30(12):1559-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of the neck in Merkel cell carcinoma of the head and neck: University of Miami experience.
  • BACKGROUND: We reviewed management of the cervical lymph nodes in patients with Merkel cell carcinoma (MCC) of the head and neck.
  • METHODS: Records of 15 patients with MCC of the head and neck area were evaluated for the type of surgical treatment, including wide local excision, sentinel lymph node (SLN) biopsy, neck dissection, postoperative radiation therapy, and clinical outcomes.
  • CONCLUSION: Wide excision and SLN biopsy for primary MCC with N0 neck is feasible for early-stage, previously untreated lesions.
  • [MeSH-major] Carcinoma, Merkel Cell / surgery. Head and Neck Neoplasms / surgery. Hospitals, University. Neck Dissection / methods. Sentinel Lymph Node Biopsy. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Feasibility Studies. Florida. Follow-Up Studies. Humans. Medical Records. Middle Aged. Postoperative Period. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc.
  • (PMID = 18767173.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Kubo H, Matsushita S, Fukushige T, Kanzaki T, Kanekura T: Spontaneous regression of recurrent and metastatic Merkel cell carcinoma. J Dermatol; 2007 Nov;34(11):773-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of recurrent and metastatic Merkel cell carcinoma.
  • Merkel cell carcinoma (MCC) is a malignant neuroendocrine tumor with a high rate of recurrence and metastasis.
  • We report an 87-year-old woman who presented with recurrent MCC on her left cheek and regional lymph node metastasis.
  • [MeSH-major] Carcinoma, Merkel Cell / secondary. Neoplasm Recurrence, Local / pathology. Neoplasm Regression, Spontaneous / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17973819.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


47. Hung SC, Bartley G, Young SA, Albers DR, Dielman DR, Anderson WH, Yokoyama W: Dietary fiber improves lipid homeostasis and modulates adipocytokines in hamsters. J Diabetes; 2009 Sep;1(3):194-206
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Hamsters were treated with HPMC (2% and 4% in a high-fat diet) or 2% or 4% microcrystalline cellulose (MCC; control diet) for 8 weeks.

  • MedlinePlus Health Information. consumer health - Dietary Fiber.
  • Hazardous Substances Data Bank. METHYL CELLULOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Blackwell Publishing Asia Pty Ltd.
  • (PMID = 20923539.001).
  • [ISSN] 1753-0407
  • [Journal-full-title] Journal of diabetes
  • [ISO-abbreviation] J Diabetes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adipokines; 0 / Adiponectin; 0 / Biomarkers; 0 / Blood Glucose; 0 / DNA, Complementary; 0 / Insulin; 0 / Leptin; 0 / Lipids; 3NXW29V3WO / Hypromellose Derivatives; 9004-67-5 / Methylcellulose
  •  go-up   go-down


48. Sandoval R, Pilkinton M, Colamonici OR: Deletion of the p107/p130-binding domain of Mip130/LIN-9 bypasses the requirement for CDK4 activity for the dissociation of Mip130/LIN-9 from p107/p130-E2F4 complex. Exp Cell Res; 2009 Oct 15;315(17):2914-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In mammalian cells, Mip130/LIN-9 specifically associates with the p107/p130-E2F4 repressor complex in G0/G1 and with B-Myb in S-phase.
  • In this report, we demonstrate that Mip130/LIN-9, Mip40/LIN-37, Mip120/LIN-54, and Sin3b form a core complex, the Mip Core Complex or LIN Complex (MCC/LINC), which is detectable in all phases of the cell cycle.

  • COS Scholar Universe. author profiles.
  • FlyBase. FlyBase .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 2006 Aug 1;312(13):2465-75 [16730350.001]
  • [Cites] Semin Cell Dev Biol. 2005 Jun;16(3):335-42 [15840442.001]
  • [Cites] J Biol Chem. 2007 Jan 5;282(1):168-75 [17098733.001]
  • [Cites] EMBO J. 2007 Jan 10;26(1):144-57 [17159899.001]
  • [Cites] Mol Cell. 2007 May 25;26(4):539-51 [17531812.001]
  • [Cites] Cell Cycle. 2007 Aug 1;6(15):1903-13 [17671431.001]
  • [Cites] Blood Cells Mol Dis. 2007 Nov-Dec;39(3):272-7 [17618148.001]
  • [Cites] Oncogene. 2007 Nov 29;26(54):7535-43 [17563750.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Sep;9(9):713-24 [18719710.001]
  • [Cites] EMBO J. 2001 Feb 1;20(3):422-32 [11157749.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2242-54 [11884610.001]
  • [Cites] J Cell Sci. 2004 May 1;117(Pt 11):2173-81 [15126619.001]
  • [Cites] Genes Dev. 2004 Jul 15;18(14):1667-80 [15256498.001]
  • [Cites] Curr Opin Genet Dev. 2004 Oct;14(5):527-32 [15380244.001]
  • [Cites] Cell. 2004 Oct 15;119(2):181-93 [15479636.001]
  • [Cites] Genes Dev. 1995 Jun 1;9(11):1340-53 [7797074.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 14;93(10):4633-7 [8643455.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):5095-100 [9144196.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):5508-20 [9271426.001]
  • [Cites] Mol Cell Biol. 1997 Dec;17(12):7268-82 [9372959.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10493-8 [9724731.001]
  • [Cites] Genes Dev. 2004 Nov 15;18(22):2699-711 [15545627.001]
  • [Cites] EMBO J. 2004 Nov 24;23(23):4615-26 [15510213.001]
  • [Cites] Genes Dev. 2004 Dec 1;18(23):2929-40 [15545624.001]
  • [Cites] EMBO J. 2004 Dec 8;23(24):4709-16 [15538380.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2796-809 [15838516.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2810-26 [15838517.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2877-98 [15838522.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2909-15 [15838524.001]
  • [Cites] Oncogene. 2006 Aug 28;25(38):5190-200 [16936737.001]
  • (PMID = 19619530.001).
  • [ISSN] 1090-2422
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / T32 DK007739; United States / NIDDK NIH HHS / DK / T32 DK07739; United States / NIGMS NIH HHS / GM / R01 GM081562; United States / NCI NIH HHS / CA / K01 CA127862; United States / NIGMS NIH HHS / GM / R01 GM054709; United States / NIGMS NIH HHS / GM / R01 GM-54709; United States / NIGMS NIH HHS / GM / R01 GM081562-01A2; United States / NIGMS NIH HHS / GM / GM081562-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cccl4 protein, mouse; 0 / Chemokine CCL4; 0 / E2F4 Transcription Factor; 0 / LIN-9 protein, mouse; 0 / Tumor Suppressor Proteins; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  • [Other-IDs] NLM/ NIHMS138706; NLM/ PMC2757496
  •  go-up   go-down


49. Radin MJ, Holycross BJ, Hoepf TM, McCune SA: Salt-induced cardiac hypertrophy is independent of blood pressure and endothelin in obese, heart failure-prone SHHF rats. Clin Exp Hypertens; 2008 Oct;30(7):541-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The SHHF/Mcc-fa(cp) (SHHF) rat model was used to examine the effect of high salt on cardiac hypertrophy and expression of endothelin (ET) and nitric oxide synthase (NOS) isoforms.
  • High salt resulted in decreased expression of preproET as well as all three NOS isoforms in the Obese, while cytokine induced NOS (iNOS) and neuronal NOS (nNOS) increased in Leans.
  • Though the salt-sensitive component of the hypertension observed in the Obese was prevented by bosentan, cardiac hypertrophy still occurred and expression of all NOS isoforms remained lower in Obese compared to Lean.
  • Endothelial NOS (eNOS) expression increased in the Lean with bosentan.
  • These studies suggest that cardiac hypertrophy is independent of the level of hypertension and may be mediated by altered production of NOS isoforms in salt-sensitive, obese SHHF.

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18855258.001).
  • [ISSN] 1525-6006
  • [Journal-full-title] Clinical and experimental hypertension (New York, N.Y. : 1993)
  • [ISO-abbreviation] Clin. Exp. Hypertens.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Endothelin Receptor Antagonists; 0 / Endothelins; 0 / Leptin; 0 / RNA, Messenger; 0 / Sodium Chloride, Dietary; 0 / Sulfonamides; EC 1.14.13.39 / Nitric Oxide Synthase; Q326023R30 / bosentan
  •  go-up   go-down


50. Barkefors I, Le Jan S, Jakobsson L, Hejll E, Carlson G, Johansson H, Jarvius J, Park JW, Li Jeon N, Kreuger J: Endothelial cell migration in stable gradients of vascular endothelial growth factor A and fibroblast growth factor 2: effects on chemotaxis and chemokinesis. J Biol Chem; 2008 May 16;283(20):13905-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endothelial cell migration in stable gradients of vascular endothelial growth factor A and fibroblast growth factor 2: effects on chemotaxis and chemokinesis.
  • However, the mechanisms by which endothelial cells integrate and respond to graded distributions of chemotactic factors are still poorly understood.
  • We have in this study investigated endothelial cell migration in response to hill-shaped gradients of vascular endothelial growth factor A (VEGFA) and fibroblast growth factor 2 (FGF2) using a novel microfluidic chemotaxis chamber (MCC).
  • Cell migration was scored at the level of individual cells using time-lapse microscopy.
  • A stable gradient of VEGFA165 ranging from 0 to 50 ng/ml over a distance of 400 microm was shown to strongly induce chemotaxis of endothelial cells of different vascular origin.
  • Furthermore, a gradient of FGF2 was able to attract venular but not arterial endothelial cells, albeit less efficiently than VEGFA165.
  • Systematic exploration of different gradient shapes led to the identification of a minimal gradient steepness required for efficient cell guidance.
  • Finally, analysis of cell migration in different regions of the applied gradients showed that chemotaxis is reduced when cells reach the high end of the gradient.
  • Our findings suggest that chemotactic growth factor gradients may instruct endothelial cells to shift toward a nonmigratory phenotype when approaching the growth factor source.
  • [MeSH-major] Endothelial Cells / cytology. Fibroblast Growth Factor 2 / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Arteries / cytology. Cell Movement. Cells, Cultured. Chemotaxis. Humans. Intercellular Signaling Peptides and Proteins / metabolism. Microscopy. Models, Biological. Phenotype. Protein Isoforms. Time Factors

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347025.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Protein Isoforms; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


51. Soh JL, Wang F, Boersen N, Pinal R, Peck GE, Carvajal MT, Cheney J, Valthorsson H, Pazdan J: Utility of multivariate analysis in modeling the effects of raw material properties and operating parameters on granule and ribbon properties prepared in roller compaction. Drug Dev Ind Pharm; 2008 Oct;34(10):1022-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A database of raw material properties was established through extensive physical and mechanical characterization of several microcrystalline cellulose (MCC) and lactose grades and their blends.

  • Hazardous Substances Data Bank. Lactose .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18777445.001).
  • [ISSN] 1520-5762
  • [Journal-full-title] Drug development and industrial pharmacy
  • [ISO-abbreviation] Drug Dev Ind Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Excipients; 0 / Tablets; 0 / microcrystalline cellulose; 9004-34-6 / Cellulose; J2B2A4N98G / Lactose
  •  go-up   go-down


52. Yamazaki T, Yamaguchi T, Sasaki N, Inoue M, Sato K, Kishimoto T: The inhibitory effect of disodium cromoglycate on the growth of Chlamydophila (Chlamydia) pneumoniae in vitro. Biol Pharm Bull; 2006 Apr;29(4):799-800
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, the inhibitory effect of DSCG on the growth of C. pneumoniae was examined by minimum inhibitory concentration (MIC) and pre-inoculation minimal cidal concentration (MCC) assays using HL cells and C. pneumoniae AR-39.
  • DSCG below the clinically relevant concentration inhibited the growth of C. pneumoniae in a dose-dependent manner in both the MCC and MIC assays.
  • The inhibitory effect was also time-dependent in the MCC assay at 20 mg/ml of DSCG.
  • [MeSH-minor] Cell Line. Culture Media. Dose-Response Relationship, Drug. Humans. Microbial Sensitivity Tests

  • Genetic Alliance. consumer health - Chlamydia.
  • Hazardous Substances Data Bank. CROMOLYN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595921.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Culture Media; Q2WXR1I0PK / Cromolyn Sodium
  •  go-up   go-down


53. Lien MH, Baldwin BT, Thareja SK, Fenske NA: Merkel cell carcinoma: clinical characteristics, markers, staging and treatment. J Drugs Dermatol; 2010 Jul;9(7):779-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma: clinical characteristics, markers, staging and treatment.
  • Merkel cell carcinoma (MCC) is a highly aggressive neoplasm affecting primarily the elderly Caucasian population.
  • Here, the authors review the typical clinical features of MCC to serve as a reference tool for clinicians in determining when a biopsy may be warranted.
  • An array of immunohistochemical markers may be utilized to differentiate MCC from other neuroendocrine tumors.
  • The staging and concomitant treatment options of MCC are discussed.
  • In addition, the authors review therapeutic advances for treatment of MCC utilizing an array of target proteins.
  • [MeSH-major] Carcinoma, Merkel Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677532.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


54. Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang LC, Peñas PF, Nghiem P: Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol; 2008 Mar;58(3):375-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features.
  • BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive skin cancer with a mortality of 33%.
  • Advanced disease at diagnosis is a poor prognostic factor, suggesting that earlier detection may improve outcome.
  • No systematic analysis has been published to define the clinical features that are characteristic of MCC.
  • OBJECTIVE: We sought to define the clinical characteristics present at diagnosis to identify features that may aid clinicians in recognizing MCC.
  • METHODS: We conducted a cohort study of 195 patients given the diagnosis of MCC between 1980 and 2007.
  • Data were collected prospectively in the majority of cases, and medical records were reviewed.
  • RESULTS: An important finding was that 88% of MCCs were asymptomatic (nontender) despite rapid growth in the prior 3 months (63% of lesions) and being red or pink (56%).
  • A majority of MCC lesions (56%) were presumed at biopsy to be benign, with a cyst/acneiform lesion being the single most common diagnosis (32%) given.
  • The median delay from lesion appearance to biopsy was 3 months (range 1-54 months), and median tumor diameter was 1.8 cm.
  • Similar to earlier studies, 81% of primary MCCs occurred on ultraviolet-exposed sites, and our cohort was elderly (90% >50 years), predominantly white (98%), and often profoundly immune suppressed (7.8%).
  • An additional novel finding was that chronic lymphocytic leukemia was more than 30-fold overrepresented among patients with MCC.
  • This study could not assess the specificity of the clinical characteristics of MCC.
  • CONCLUSIONS: To our knowledge, this study is the first to define clinical features that may serve as clues in the diagnosis of MCC.
  • The most significant features can be summarized in an acronym: AEIOU (asymptomatic/lack of tenderness, expanding rapidly, immune suppression, older than 50 years, and ultraviolet-exposed site on a person with fair skin).
  • In our series, 89% of primary MCCs had 3 or more of these findings.
  • Although MCC is uncommon, when present in combination, these features may indicate a concerning process that would warrant biopsy.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol. 1984 Nov;110(11):707-12 [6487123.001]
  • [Cites] Am J Clin Oncol. 2003 Dec;26(6):531-4 [14663367.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):153-8 [10067813.001]
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):1-4 [15611998.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2300-9 [15800320.001]
  • [Cites] Br J Dermatol. 2005 Jul;153(1):229-32 [16029370.001]
  • [Cites] J Invest Dermatol. 2005 Aug;125(2):175-82 [16098025.001]
  • [Cites] BMC Cancer. 2005;5:106 [16111484.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):685-90 [16785370.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):693-700 [16785371.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1043-7 [17369567.001]
  • [Cites] Diagn Cytopathol. 2007 May;35(5):293-5 [17427219.001]
  • [Cites] J Am Acad Dermatol. 2007 Jul;57(1):166-9 [17482714.001]
  • [Cites] J Invest Dermatol. 2007 Sep;127(9):2100-3 [17700621.001]
  • [Cites] Transplantation. 1999 Dec 15;68(11):1717-21 [10609948.001]
  • [Cites] Br J Dermatol. 2000 Mar;142(3):525-8 [10735964.001]
  • [Cites] Lancet. 2002 Feb 9;359(9305):497-8 [11853800.001]
  • [Cites] Transplantation. 2002 Jun 15;73(11):1849-50 [12085015.001]
  • [Cites] Transplant Proc. 2002 Aug;34(5):1780-1 [12176573.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Cell Cycle. 2003 May-Jun;2(3):196-8 [12734424.001]
  • [Cites] J Am Acad Dermatol. 2003 Nov;49(5):832-41 [14576661.001]
  • [Cites] J Clin Pathol. 2003 Dec;56(12):970-1 [14645362.001]
  • [Cites] N Engl J Med. 1998 Oct 22;339(17):1247-8 [9786759.001]
  • (PMID = 18280333.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093683-04; United States / NIAMS NIH HHS / AR / K02 AR050993-04; United States / NIAMS NIH HHS / AR / AR050993-04; United States / NCI NIH HHS / CA / P50 CA093683-04; United States / NCI NIH HHS / CA / P50 CA093683; United States / NIAMS NIH HHS / AR / K02 AR050993; United States / NIAMS NIH HHS / AR / AR050993-02; United States / NIAMS NIH HHS / AR / K02 AR050993-02; United States / NIAMS NIH HHS / AR / AR050993-03; United States / NIAMS NIH HHS / AR / K02-AR050993; United States / NIAMS NIH HHS / AR / K02 AR050993-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS41599; NLM/ PMC2335370
  •  go-up   go-down


55. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis Ch, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V: FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer; 2006 Mar 27;94(6):798-805
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG).
  • To compare the efficacy and toxicity of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOXIRI) vs irinotecan and 5-FU/LV (FOLFIRI) as first-line treatment of patients with metastatic colorectal cancer (MCC).
  • A total of 283 chemotherapy-naïve patients with MCC were enrolled (FOLFIRI arm: n=146; FOLFOXIRI arm: n=137).
  • There was no difference in terms of overall survival (median OS: 19.5 and 21.5 months, for FOLFIRI and FOLFOXIRI, respectively; P=0.337), median time to disease progression (FOLFIRI: 6.9 and FOLFOXIRI: 8.4 months; P=0.17), response rates (33.6 and 43% for FOLFIRI and FOLFOXIRI, respectively; P=0.168).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Injections, Intravenous. Leucovorin / administration & dosage. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Oncology. 2005;69(5):384-90 [16319509.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343(13):905-14 [11006366.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):308-17 [11886010.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2651-7 [12039926.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):4006-14 [12351598.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1209-14 [15051767.001]
  • [Cites] Biometrics. 1975 Mar;31(1):103-15 [1100130.001]
  • [Cites] Biometrics. 1979 Sep;35(3):549-56 [497341.001]
  • [Cites] Stat Med. 1982 Apr-Jun;1(2):121-9 [7187087.001]
  • [Cites] Cancer Res. 1989 Sep 15;49(18):5077-82 [2548710.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1407-18 [2476530.001]
  • [Cites] J Natl Cancer Inst. 1990 Jun 20;82(12):1046-50 [2348469.001]
  • [Cites] J Natl Cancer Inst. 1994 Jun 1;86(11):836-42 [8182764.001]
  • [Cites] Biochem Pharmacol. 1996 Dec 24;52(12):1855-65 [8951344.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):808-15 [9053508.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):418-26 [9469324.001]
  • [Cites] Br J Cancer. 1998 Jun;77 Suppl 4:1-3 [9647611.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3169-78 [9738589.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1053-71 [9834817.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3545-51 [15908665.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • (PMID = 16508637.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; FOLFOXIRI protocol; IFL protocol
  • [Other-IDs] NLM/ PMC2361370
  •  go-up   go-down


56. Manten J, Rijk M, Jansen R: Merkel cell carcinoma; a rare, aggressive, cutaneous malignancy. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma; a rare, aggressive, cutaneous malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21686689.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027524
  •  go-up   go-down


57. Brunner M, Thurnher D, Pammer J, Heiduschka G, Petzelbauer P, Schmid C, Schneider S, Erovic BM: Expression of hedgehog signaling molecules in Merkel cell carcinoma. Head Neck; 2010 Mar;32(3):333-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hedgehog signaling molecules in Merkel cell carcinoma.
  • METHODS: One tissue microarray with triplets of 28 samples from 25 patients with Merkel cell carcinoma (MCC) was constructed.
  • Six samples of normal skin and 5 samples of normal oral mucosa served as controls.
  • RESULTS: All investigated proteins were frequently and intensely overexpressed in MCCs (Sonic hedgehog, 93%; Indian hedgehog, 84%; Patched, 86%; Smoothened, 79%; Gli-1, 79%; Gli-2, 79%; Gli-3, 86%) compared with control samples.
  • CONCLUSIONS: Our results indicate that the Hedgehog signaling pathway is strongly activated in MCC and thus may play a role in carcinogenesis.
  • [MeSH-major] Carcinoma, Merkel Cell / metabolism. Head and Neck Neoplasms / metabolism. Hedgehog Proteins / metabolism. Receptors, Cell Surface / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19644931.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / GLI2 protein, human; 0 / GLI3 protein, human; 0 / Hedgehog Proteins; 0 / IHH protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / SHH protein, human; 0 / SMO protein, human; 0 / Transcription Factors; 0 / patched receptors
  •  go-up   go-down


58. Newton JM, Bazzigialuppi M, Podczeck F, Booth S, Clarke A: The rheological properties of self-emulsifying systems, water and microcrystalline cellulose. Eur J Pharm Sci; 2005 Oct;26(2):176-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rheological properties of mixtures of equal parts of a range of ratios of a self-emulsifying system (MP) and water (W) added to microcrystalline cellulose (MCC), have been measured by an extrusion capillary rheometer.
  • The results indicate that there are three regions of behaviour of the systems, which are all significantly different from the mixtures containing only W and MCC.
  • The behaviour of the 46% MP system is intermediate between these systems and the high MP concentrations (69, 80 and 92%).
  • These latter systems show less resistance to shear and elongational flow than the first group of concentrations, but show considerably higher levels of elasticity.
  • Changes in the ratio of the MPW to MCC for a system for a single level of MP (46%) resulted in a change in the values of the rheological parameters but not the type of behaviour.

  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16046106.001).
  • [ISSN] 0928-0987
  • [Journal-full-title] European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • [ISO-abbreviation] Eur J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Diglycerides; 0 / Emulsions; 0 / Excipients; 0 / Glycerides; 0 / Polysorbates; 0 / microcrystalline cellulose; 059QF0KO0R / Water; 9004-34-6 / Cellulose
  •  go-up   go-down


59. Ha TJ, Kohn AB, Bobkova YV, Moroz LL: Molecular characterization of NMDA-like receptors in Aplysia and Lymnaea: relevance to memory mechanisms. Biol Bull; 2006 Jun;210(3):255-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our in situ hybridization data indicate highly abundant, but predominantly neuron-specific expression of molluscan NR1-type receptors in all central ganglia, including identified motor neurons in the buccal and abdominal ganglia as well as groups of mechanosensory cells.
  • AcNR1 transcripts were detected extrasynaptically in the neurites of metacerebral cells of Aplysia.

  • MedlinePlus Health Information. consumer health - Memory.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16801499.001).
  • [ISSN] 0006-3185
  • [Journal-full-title] The Biological bulletin
  • [ISO-abbreviation] Biol. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NR1 NMDA receptor; 0 / Protein Subunits; 0 / Receptors, N-Methyl-D-Aspartate
  •  go-up   go-down


60. Koscielny S: [The Merkel cell carcinoma]. Laryngorhinootologie; 2008 Mar;87(3):205-10; quiz 211
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The Merkel cell carcinoma].
  • The Merkel cell carcinoma is a rare tumor of the subdermal tissue.
  • Its origin are Merkel cells or the subcutaneous pluripotential stem cells.
  • The etiology of the tumor is unknown, however, exposition to UV radiation and immunosuppression are relevant predisposing factors.
  • Clinically, a subcutaneous rapidly growing tumor with or without enlarged lymph nodes is seen.
  • Surgical resection of the tumor combined with neck dissection followed by radiation therapy is the current therapy of choice.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Head and Neck Neoplasms / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Humans. Lymphatic Metastasis. Neck Dissection. Neoplasm Staging. Radiotherapy, Adjuvant. Skin / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18322889.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Tamblyn R, Abrahamowicz M, Dauphinee D, Wenghofer E, Jacques A, Klass D, Smee S, Blackmore D, Winslade N, Girard N, Du Berger R, Bartman I, Buckeridge DL, Hanley JA: Physician scores on a national clinical skills examination as predictors of complaints to medical regulatory authorities. JAMA; 2007 Sep 5;298(9):993-1001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physician scores on a national clinical skills examination as predictors of complaints to medical regulatory authorities.
  • To address this problem, licensure assessment has been reformed in Canada and the United States, including a national standardized assessment of patient-physician communication and clinical history taking and examination skills.
  • OBJECTIVE: To assess whether patient-physician communication examination scores in the clinical skills examination predicted future complaints in medical practice.
  • DESIGN, SETTING, AND PARTICIPANTS: Cohort study of all 3424 physicians taking the Medical Council of Canada clinical skills examination between 1993 and 1996 who were licensed to practice in Ontario and/or Quebec.
  • MAIN OUTCOME MEASURE: Patient complaints against study physicians that were filed with medical regulatory authorities in Ontario or Quebec and retained after investigation.
  • CONCLUSION: Scores achieved in patient-physician communication and clinical decision making on a national licensing examination predicted complaints to medical regulatory authorities.


62. Johnson EM: Structural evaluation of new human polyomaviruses provides clues to pathobiology. Trends Microbiol; 2010 May;18(5):215-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the past three years, remarkable discoveries have added three new human polyomaviruses (KI virus (KIV), WU virus (WUV) and Merkel cell virus (MCV)) to a class that previously had only two disease-causing members (BK virus (BKV) and JC virus (JCV)) identified.
  • Two monkey polyomaviruses, simian virus (SV)40 and B-cell lymphotropic polyomavirus (LPV) are also present in humans.
  • Of these viruses, only MCV has thus far been strongly linked to cancer.
  • Marshalled evidence from diverse sources implicates MCV as an etiological agent of Merkel cell carcinoma.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] J Virol. 2008 Oct;82(20):9823-8 [18684810.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16272-7 [18812503.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16063-4 [18922770.001]
  • [Cites] Cell Cycle. 2009 Feb 1;8(3):1-7 [19182532.001]
  • [Cites] Emerg Infect Dis. 2009 Mar;15(3):492-4 [19239774.001]
  • [Cites] J Neurovirol. 2009 Jan;15(1):51-6 [19043822.001]
  • [Cites] Virus Res. 2009 Apr;141(1):71-80 [19200446.001]
  • [Cites] PLoS Pathog. 2009 Mar;5(3):e1000363 [19325891.001]
  • [Cites] Mod Pathol. 2009 Apr;22(4):516-21 [19252474.001]
  • [Cites] J Pathol. 2009 May;218(1):48-56 [19291712.001]
  • [Cites] J Natl Compr Canc Netw. 2009 Mar;7(3):333-9 [19401065.001]
  • [Cites] J Invest Dermatol. 2009 Jun;129(6):1547-55 [19020549.001]
  • [Cites] Virology. 2009 Jan 20;383(2):183-7 [19046593.001]
  • [Cites] PLoS Genet. 2009 Feb;5(2):e1000368 [19197354.001]
  • [Cites] Virology. 2009 Feb 20;384(2):352-9 [19101707.001]
  • [Cites] Virology. 2009 Feb 20;384(2):260-5 [19135222.001]
  • [Cites] Virology. 2009 Feb 20;384(2):274-84 [19150725.001]
  • [Cites] J Virol. 2009 Jun;83(11):5708-17 [19297467.001]
  • [Cites] Semin Cancer Biol. 2009 Aug;19(4):218-28 [19505649.001]
  • [Cites] J Clin Virol. 2009 Jul;45(3):249-54 [19515607.001]
  • [Cites] J Natl Cancer Inst. 2009 Jul 1;101(13):938-45 [19535775.001]
  • [Cites] J Clin Virol. 2009 Aug;45(4):292-5 [19464943.001]
  • [Cites] J Gen Virol. 2009 Aug;90(Pt 8):2005-14 [19420158.001]
  • [Cites] Semin Neurol. 1999;19(2):193-200 [10718540.001]
  • [Cites] Transplant Proc. 2002 Aug;34(5):1780-1 [12176573.001]
  • [Cites] Semin Cancer Biol. 2004 Dec;14(6):453-71 [15489139.001]
  • [Cites] Cell. 1978 Jan;13(1):165-79 [202398.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Dec;76(12):6128-31 [230499.001]
  • [Cites] Ann Intern Med. 1980 Mar;92(3):373-8 [6243896.001]
  • [Cites] J Med Virol. 1981;6(4):301-8 [7017066.001]
  • [Cites] J Virol. 1983 Apr;46(1):170-6 [6298454.001]
  • [Cites] J Virol. 1984 Mar;49(3):925-37 [6321773.001]
  • [Cites] EMBO J. 1982;1(8):945-51 [6329717.001]
  • [Cites] Nature. 1985 Mar 7-13;314(6006):111-4 [2983228.001]
  • [Cites] J Biol Chem. 1988 Jan 5;263(1):383-92 [2826443.001]
  • [Cites] Nucleic Acids Res. 1988 Nov 25;16(22):10881-90 [2849754.001]
  • [Cites] Nature. 1989 Apr 20;338(6217):658-62 [2539565.001]
  • [Cites] J Virol. 1989 Sep;63(9):3961-73 [2760986.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]
  • [Cites] Med Hypotheses. 1995 Jan;44(1):28-31 [7776898.001]
  • [Cites] J Biol Chem. 1995 Oct 13;270(41):24352-60 [7592647.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14112-7 [8943069.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3679-84 [9108037.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):153-8 [10067813.001]
  • [Cites] J Cell Physiol. 2005 Jul;204(1):1-7 [15573377.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):682-6 [15931223.001]
  • [Cites] N Engl J Med. 2005 Jul 28;353(4):414-6 [15947082.001]
  • [Cites] Brain Res Brain Res Rev. 2005 Dec 1;50(1):69-85 [15982744.001]
  • [Cites] Diagn Cytopathol. 2006 Mar;34(3):201-3 [16470860.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Cell Mol Life Sci. 2006 Apr;63(7-8):865-76 [16501889.001]
  • [Cites] Transpl Infect Dis. 2006 Jun;8(2):76-85 [16734630.001]
  • [Cites] J Virol. 2007 Apr;81(8):4130-6 [17287263.001]
  • [Cites] PLoS Pathog. 2007 May 4;3(5):e64 [17480120.001]
  • [Cites] J Clin Virol. 2007 Dec;40(4):307-11 [17997354.001]
  • [Cites] Emerg Infect Dis. 2007 Dec;13(12):1936-8 [18258052.001]
  • [Cites] Science. 2008 Feb 22;319(5866):1096-100 [18202256.001]
  • [Cites] Curr Opin Struct Biol. 2008 Apr;18(2):243-57 [18329872.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Annu Rev Med. 2009;60:167-79 [19630570.001]
  • [Cites] Am J Surg Pathol. 2009 Sep;33(9):1378-85 [19609205.001]
  • [Cites] J Virol. 2009 Oct;83(19):10275-9 [19605473.001]
  • [Cites] Emerg Infect Dis. 2009 Sep;15(9):1496-8 [19788824.001]
  • [Cites] J Virol. 2009 Dec;83(23):12118-28 [19759150.001]
  • [Cites] Virology. 2009 Nov 25;394(2):183-93 [19782382.001]
  • [Cites] Int J Cancer. 2010 Feb 1;126(3):796-8 [19637243.001]
  • [Cites] Int J Cancer. 2010 May 1;126(9):2240-6 [19551862.001]
  • [Cites] Int J Cancer. 2010 Jun 15;126(12):2991-6 [19588496.001]
  • [Cites] Cell Host Microbe. 2008 Jun 12;3(6):375-87 [18541214.001]
  • [Cites] Nat Rev Genet. 2008 Jul;9(7):503-7 [18490927.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5009-13 [18593898.001]
  • [Cites] J Clin Microbiol. 2008 Jul;46(7):2461-2 [18480226.001]
  • [Cites] J Virol Methods. 2008 Oct;153(1):70-3 [18639584.001]
  • (PMID = 20176487.001).
  • [ISSN] 1878-4380
  • [Journal-full-title] Trends in microbiology
  • [ISO-abbreviation] Trends Microbiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA055219-14; United States / NCI NIH HHS / CA / R01 CA055219-14; United States / NINDS NIH HHS / NS / R01 NS035000; United States / NINDS NIH HHS / NS / R01 NS035000-13; United States / NCI NIH HHS / CA / R01 CA055219; United States / NINDS NIH HHS / NS / NS035000-13
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Viral Proteins; 0 / Virulence Factors
  • [Number-of-references] 73
  • [Other-IDs] NLM/ NIHMS182241; NLM/ PMC2864792
  •  go-up   go-down


63. Kazakov T, Vondenhoff GH, Datsenko KA, Novikova M, Metlitskaya A, Wanner BL, Severinov K: Escherichia coli peptidase A, B, or N can process translation inhibitor microcin C. J Bacteriol; 2008 Apr;190(7):2607-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The heptapeptide-nucleotide microcin C (McC) targets aspartyl-tRNA synthetase.
  • Upon its entry into a susceptible cell, McC is processed to release a nonhydrolyzable aspartyl-adenylate that inhibits aspartyl-tRNA synthetase, leading to the cessation of translation and cell growth.
  • Here, we surveyed Escherichia coli cells with singly, doubly, and triply disrupted broad-specificity peptidase genes to show that any of three nonspecific oligopeptidases (PepA, PepB, or PepN) can effectively process McC.
  • We also show that the rate-limiting step of McC processing in vitro is deformylation of the first methionine residue of McC.

  • BioCyc. gene/protein/disease-specific - pepN .
  • BioCyc. gene/protein/disease-specific - pepB .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. ADENOSINE 5'-PHOSPHATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6640-5 [10829079.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1995;60:461-78 [8824420.001]
  • [Cites] Biochimie. 2002 May-Jun;84(5-6):521-9 [12423796.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Sep;47(9):2868-74 [12936987.001]
  • [Cites] J Bacteriol. 1978 Aug;135(2):342-7 [355221.001]
  • [Cites] J Bacteriol. 1983 Oct;156(1):308-15 [6352681.001]
  • [Cites] Nature. 1994 May 26;369(6478):281 [8183363.001]
  • [Cites] FEBS Lett. 1995 Jan 9;357(3):235-8 [7835418.001]
  • [Cites] J Biol Chem. 1995 Oct 6;270(40):23520-32 [7559516.001]
  • [Cites] J Mol Biol. 1999 Jul 16;290(3):607-14 [10395817.001]
  • [Cites] Bioorg Med Chem. 2005 Jan 3;13(1):69-75 [15582453.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1533 [16141066.001]
  • [Cites] J Biol Chem. 2006 Jun 30;281(26):18033-42 [16574659.001]
  • [Cites] J Bacteriol. 2007 Mar;189(5):2114-8 [17158672.001]
  • [Cites] Mol Microbiol. 2007 Sep;65(6):1380-94 [17711420.001]
  • [Cites] J Bacteriol. 2007 Nov;189(22):8361-5 [17873039.001]
  • [Cites] Biochimie. 2002 May-Jun;84(5-6):511-9 [12423795.001]
  • (PMID = 18223070.001).
  • [ISSN] 1098-5530
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U54 AI057158; United States / NIAID NIH HHS / AI / U54-AI057158
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Bacteriocins; 0 / Escherichia coli Proteins; 148265-34-3 / pepN protein, Bacteria; 19046-78-7 / aspartyl adenylate; 30KYC7MIAI / Aspartic Acid; 415SHH325A / Adenosine Monophosphate; EC 3.4.- / Peptide Hydrolases; EC 3.4.- / oligopeptidase; EC 3.4.11.- / Aminopeptidases; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.83 / oligopeptidase B; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.99.- / oligopeptidase A; EC 6.1.1.12 / Aspartate-tRNA Ligase
  • [Other-IDs] NLM/ PMC2293190
  •  go-up   go-down


64. Miller SJ, Alam M, Andersen J, Berg D, Bichakjian CK, Bowen G, Cheney RT, Glass LF, Grekin RC, Hallahan DE, Kessinger A, Lee NY, Liegeois N, Lydiatt DD, Michalski J, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Olencki T, Oseroff AR, Perlis CS, Rosenberg EW, Shaha AR, Urist MM, Wang LC, NCCN Merkel Cell Carcinoma Panel: Merkel cell carcinoma. J Natl Compr Canc Netw; 2009 Mar;7(3):322-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19401064.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] United States
  •  go-up   go-down


65. Koutkias VG, Chouvarda I, Maglaveras N: A multiagent system enhancing home-care health services for chronic disease management. IEEE Trans Inf Technol Biomed; 2005 Dec;9(4):528-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multiagent system enhancing home-care health services for chronic disease management.
  • In this paper, a multiagent system (MAS) is presented, aiming to enhance monitoring, surveillance, and educational services of a generic medical contact center (MCC) for chronic disease management.
  • In such a home-care scenario, a persistent need arises for efficiently monitoring the patient contacts and the MCC's functionality, in order to effectively manage and interpret the large volume of medical data collected during the patient sessions with the system, and to assess the use of MCC resources.
  • Specifically, the objective of the MAS is to monitor the MCC environment, detect important cases, and inform the healthcare and administrative personnel via alert messages, notifications, recommendations, and reports, prompting them for actions.
  • The main aim of this paper is to present the overall design and implementation of a proposed MAS, emphasizing its functional model and architecture, as well as on the agent interactions and the knowledge-sharing mechanism incorporated, in the context of a generic MCC.
  • [MeSH-major] Artificial Intelligence. Decision Support Systems, Clinical / organization & administration. Diagnosis, Computer-Assisted / methods. Home Care Services / organization & administration. Medical Records Systems, Computerized / organization & administration. Telemedicine / methods. Therapy, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Home Care Services.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16379370.001).
  • [ISSN] 1089-7771
  • [Journal-full-title] IEEE transactions on information technology in biomedicine : a publication of the IEEE Engineering in Medicine and Biology Society
  • [ISO-abbreviation] IEEE Trans Inf Technol Biomed
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


66. Woegerbauer M, Thurnher D, Houben R, Pammer J, Kloimstein P, Heiduschka G, Petzelbauer P, Erovic BM: Expression of the tetraspanins CD9, CD37, CD63, and CD151 in Merkel cell carcinoma: strong evidence for a posttranscriptional fine-tuning of CD9 gene expression. Mod Pathol; 2010 May;23(5):751-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the tetraspanins CD9, CD37, CD63, and CD151 in Merkel cell carcinoma: strong evidence for a posttranscriptional fine-tuning of CD9 gene expression.
  • Tetraspanins including CD9, CD37, CD63, and CD151 are linked to cellular adhesion, cell differentiation, migration, carcinogenesis, and tumor progression.
  • The aim of the study was to detect, quantify, and evaluate the prognostic value of these tetraspanins in Merkel cell carcinoma and to study the regulation of CD9 mRNA expression in Merkel cell carcinoma cell lines in detail.
  • Immunohistochemical staining of 28 Merkel cell carcinoma specimens from 25 patients showed a significant correlation of CD9 (P=0.03) and CD151 (P=0.043) expression to overall survival.
  • CD9 and CD63 expression correlated significantly to patients' disease-free interval (P=0.017 and P=0.058).
  • Of primary Merkel cell carcinoma tumors, 42% were CD9 positive in contrast to only 21% of the subcutaneous in-transit metastases.
  • Characterization of the 5' untranslated region (UTR) of the CD9 mRNA from two cultured Merkel cell carcinoma cell lines revealed the presence of two major RNA species differing only in the length of their 5' termini (183 versus 102 nucleotides).
  • Quantitative data by real-time RT-PCR not only indicated a reduction of CD9 mRNA but also a distinct quantitative shift toward the long 5' UTR in CD9 receptor negative cells.
  • These observations provide an example for a posttranscriptional fine-tuning of CD9 gene expression in tumor cells.
  • [MeSH-major] Antigens, CD / genetics. Antigens, Neoplasm / genetics. Carcinoma, Merkel Cell / genetics. Membrane Glycoproteins / genetics. Platelet Membrane Glycoproteins / genetics. RNA Processing, Post-Transcriptional / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Antigens, CD151. Antigens, CD63. Antigens, CD9. Cell Line, Tumor. Cells, Cultured. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Regression Analysis. Reverse Transcriptase Polymerase Chain Reaction. Tetraspanins. Untranslated Regions / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20118909.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD151; 0 / Antigens, CD63; 0 / Antigens, CD9; 0 / Antigens, Neoplasm; 0 / CD151 protein, human; 0 / CD37 protein, human; 0 / CD63 protein, human; 0 / CD9 protein, human; 0 / Membrane Glycoproteins; 0 / Platelet Membrane Glycoproteins; 0 / RNA, Messenger; 0 / Tetraspanins; 0 / Untranslated Regions
  •  go-up   go-down


67. Koljonen V, Tukiainen E, Haglund C, Böhling T: Proliferative activity detected by Ki67 correlates with poor outcome in Merkel cell carcinoma. Histopathology; 2006 Nov;49(5):551-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferative activity detected by Ki67 correlates with poor outcome in Merkel cell carcinoma.
  • [MeSH-major] Carcinoma, Merkel Cell / secondary. Ki-67 Antigen / analysis. Skin Neoplasms / pathology
  • [MeSH-minor] Cell Proliferation. Disease Progression. Humans. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064309.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


68. Loibl M, Grossmann G, Stradalova V, Klingl A, Rachel R, Tanner W, Malinsky J, Opekarová M: C terminus of Nce102 determines the structure and function of microdomains in the Saccharomyces cerevisiae plasma membrane. Eukaryot Cell; 2010 Aug;9(8):1184-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The plasma membrane of the yeast Saccharomyces cerevisiae contains stably distributed lateral domains of specific composition and structure, termed MCC (membrane compartment of arginine permease Can1).
  • Accumulation of Can1 and other specific proton symporters within MCC is known to regulate the turnover of these transporters and is controlled by the presence of another MCC protein, Nce102.
  • We show that in an NCE102 deletion strain the function of Nce102 in directing the specific permeases into MCC can be complemented by overexpression of the NCE102 close homolog FHN1 (the previously uncharacterized YGR131W) as well as by distant Schizosaccharomyces pombe homolog fhn1 (SPBC1685.13).
  • Deletion of the C terminus or even of its last 6 amino acids does not disturb protein trafficking, but it seriously affects the formation of MCC.
  • We show that the C-terminal part of the Nce102 protein is necessary for localization of both Nce102 itself and Can1 to MCC and also for the formation of furrow-like membrane invaginations, the characteristic ultrastructural feature of MCC domains.
  • [MeSH-minor] Amino Acid Sequence. Amino Acid Transport Systems, Basic / metabolism. Cell Surface Extensions / metabolism. Cell Surface Extensions / ultrastructure. Molecular Sequence Data. Mutant Proteins / chemistry. Mutant Proteins / metabolism. Protein Transport. Sequence Homology, Amino Acid. Structure-Activity Relationship

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biol Cell. 2000 Dec;11(12):4241-57 [11102521.001]
  • [Cites] Gene. 1988 Dec 30;74(2):527-34 [3073106.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):10663-9 [11139575.001]
  • [Cites] Am J Physiol Cell Physiol. 2001 Jul;281(1):C215-23 [11401844.001]
  • [Cites] Biopolymers. 1990;30(1-2):107-20 [2224046.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] FEBS Lett. 1990 Dec 17;277(1-2):185-8 [2269352.001]
  • [Cites] J Mol Biol. 1991 Mar 20;218(2):397-412 [2010917.001]
  • [Cites] Proteins. 1991;10(3):219-28 [1881878.001]
  • [Cites] J Cell Biol. 1996 Jun;133(5):1017-26 [8655575.001]
  • [Cites] EMBO J. 1997 Apr 15;16(8):1832-41 [9155009.001]
  • [Cites] Science. 1997 Oct 24;278(5338):680-6 [9381177.001]
  • [Cites] Yeast. 1998 Jan 30;14(2):115-32 [9483801.001]
  • [Cites] J Biol Chem. 1999 Mar 26;274(13):9068-75 [10085156.001]
  • [Cites] J Cell Sci. 2004 Dec 1;117(Pt 25):6031-41 [15536122.001]
  • [Cites] Archaea. 2002 Mar;1(1):9-18 [15803654.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):998-1003 [16496001.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11142-7 [16847258.001]
  • [Cites] FEBS Lett. 2006 Oct 9;580(23):5559-64 [16996501.001]
  • [Cites] EMBO J. 2007 Jan 10;26(1):1-8 [17170709.001]
  • [Cites] Bioinformatics. 2007 Nov 1;23(21):2947-8 [17846036.001]
  • [Cites] J Biol Chem. 2008 Apr 18;283(16):10433-44 [18296441.001]
  • [Cites] Biophys J. 2008 Sep;95(5):2325-39 [18515373.001]
  • [Cites] J Cell Biol. 2008 Dec 15;183(6):1075-88 [19064668.001]
  • [Cites] Mol Biol Cell. 2009 Feb;20(3):809-18 [19037108.001]
  • [Cites] J Cell Biol. 2009 Jun 29;185(7):1227-42 [19564405.001]
  • [Cites] J Cell Sci. 2009 Aug 15;122(Pt 16):2887-94 [19638406.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22245-50 [20080790.001]
  • [Cites] Yeast. 2010 Aug;27(8):473-8 [20641012.001]
  • [Cites] Mol Biol Cell. 2001 Oct;12(10):2987-3003 [11598186.001]
  • [Cites] Methods Enzymol. 2002;350:87-96 [12073338.001]
  • [Cites] J Biol Chem. 2003 Mar 21;278(12):10208-13 [12524434.001]
  • [Cites] Yeast. 2003 Apr 15;20(5):407-15 [12673624.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7460-4 [12810948.001]
  • [Cites] Mol Biol Cell. 2003 Nov;14(11):4427-36 [14551254.001]
  • [Cites] Gene. 1987;52(2-3):225-33 [3038686.001]
  • [Cites] J Cell Biol. 1987 Aug;105(2):633-45 [3305520.001]
  • [Cites] J Mol Biol. 2001 Jan 19;305(3):567-80 [11152613.001]
  • (PMID = 20581291.001).
  • [ISSN] 1535-9786
  • [Journal-full-title] Eukaryotic cell
  • [ISO-abbreviation] Eukaryotic Cell
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acid Transport Systems, Basic; 0 / CAN1 protein, S cerevisiae; 0 / Mutant Proteins; 0 / NCE102 protein, S cerevisiae; 0 / Saccharomyces cerevisiae Proteins
  • [Other-IDs] NLM/ PMC2918937
  •  go-up   go-down


69. Côté P, Abatzoglou N: Powder and other divided solids mixing. Scale-up and parametric study of a ribbon blender used in pharmaceutical powders mixing. Pharm Dev Technol; 2006 Feb;11(1):29-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a laboratory-scale model ribbon blender, built by scaling down a real industrial unit, powder mixtures composed of white and blue microcrystalline cellulose (MCC) were blended.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16544907.001).
  • [ISSN] 1083-7450
  • [Journal-full-title] Pharmaceutical development and technology
  • [ISO-abbreviation] Pharm Dev Technol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Excipients; 0 / Powders; 0 / microcrystalline cellulose; 9004-34-6 / Cellulose
  •  go-up   go-down


70. Scott DR: Apparent response of cutaneous Merkel cell tumor to topical imiquimod. Cutis; 2006 Feb;77(2):109-10; author reply 110
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apparent response of cutaneous Merkel cell tumor to topical imiquimod.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Merkel Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cutis. 2004 Dec;74(6):350-6 [15663071.001]
  • (PMID = 16570674.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


71. Touzé A, Gaitan J, Arnold F, Cazal R, Fleury MJ, Combelas N, Sizaret PY, Guyetant S, Maruani A, Baay M, Tognon M, Coursaget P: Generation of Merkel cell polyomavirus (MCV)-like particles and their application to detection of MCV antibodies. J Clin Microbiol; 2010 May;48(5):1767-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generation of Merkel cell polyomavirus (MCV)-like particles and their application to detection of MCV antibodies.
  • The genome of a new human polyomavirus, known as Merkel cell polyomavirus (MCV), has recently been reported to be integrated within the cellular DNA of Merkel cell carcinoma (MCC), a rare human skin cancer.
  • To investigate MCV seroprevalence in the general population, we expressed three different MCV VP1 in insect cells using recombinant baculoviruses.
  • [MeSH-major] Antibodies, Viral / blood. Antigens, Viral. Carcinoma, Merkel Cell / virology. Polyomavirus / immunology. Polyomavirus Infections / diagnosis. Virosomes
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Animals. BK Virus / immunology. Baculoviridae / genetics. Cell Line. Cross Reactions. Female. Gene Expression. Genetic Vectors. Humans. Insects. Male. Merkel Cells / virology. Mice. Microscopy, Electron, Transmission. Sensitivity and Specificity. Young Adult

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 2001 Jan 5;279(1):361-9 [11145917.001]
  • [Cites] J Gen Virol. 2001 Dec;82(Pt 12):3005-9 [11714977.001]
  • [Cites] J Med Virol. 2003 Sep;71(1):115-23 [12858417.001]
  • [Cites] J Med Virol. 1989 Jun;28(2):118-23 [2544676.001]
  • [Cites] Biophys J. 1989 Nov;56(5):887-900 [2557933.001]
  • [Cites] J Virol. 1993 Dec;67(12):6929-36 [8230414.001]
  • [Cites] J Clin Microbiol. 1998 Jul;36(7):2046-51 [9650960.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):247-50 [18449881.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16272-7 [18812503.001]
  • [Cites] PLoS Pathog. 2009 Mar;5(3):e1000363 [19325891.001]
  • [Cites] Acta Oncol. 2009;48(4):605-9 [19137462.001]
  • [Cites] J Infect Dis. 2009 Mar 15;199(6):837-46 [19434930.001]
  • [Cites] Emerg Infect Dis. 2009 Jun;15(6):960-2 [19523303.001]
  • [Cites] Int J Cancer. 2009 Sep 15;125(6):1250-6 [19499548.001]
  • [Cites] PLoS Pathog. 2009 Sep;5(9):e1000578 [19750217.001]
  • [Cites] J Natl Cancer Inst. 2009 Nov 4;101(21):1510-22 [19776382.001]
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):1-4 [15611998.001]
  • [Cites] Adv Exp Med Biol. 2006;577:73-84 [16626028.001]
  • [Cites] Arch Virol. 2006 Aug;151(8):1511-23 [16508703.001]
  • [Cites] J Biochem. 2007 Feb;141(2):279-86 [17283011.001]
  • [Cites] J Virol. 2007 Apr;81(8):4130-6 [17287263.001]
  • [Cites] PLoS Pathog. 2007 May 4;3(5):e64 [17480120.001]
  • [Cites] J Invest Dermatol. 2007 Sep;127(9):2100-3 [17700621.001]
  • [Cites] Science. 2008 Feb 22;319(5866):1096-100 [18202256.001]
  • (PMID = 20181914.001).
  • [ISSN] 1098-660X
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antigens, Viral; 0 / Virosomes
  • [Other-IDs] NLM/ PMC2863896
  •  go-up   go-down


72. Suekane T, Ikura Y, Watanabe K, Arimoto J, Iwasa Y, Sugama Y, Kayo S, Sugioka K, Naruko T, Maeda K, Hirakawa K, Arakawa T, Ueda M: Phenotypic change and accumulation of smooth muscle cells in strictures in Crohn's disease: relevance to local angiotensin II system. J Gastroenterol; 2010 Aug;45(8):821-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic change and accumulation of smooth muscle cells in strictures in Crohn's disease: relevance to local angiotensin II system.
  • BACKGROUND: Intestinal stricture lesions in Crohn's disease are characterized as submucosal fibromuscular accumulation.
  • There has been a controversy about whether the fibrogenic cells in stricture lesions in Crohn's disease originate from a smooth muscle cell or a fibroblast lineage.
  • (1) the origin of the fibrogenic cells in stricture lesions; and (2) the roles of the local angiotensin II system, including mast cell chymase, in stricture formation.
  • METHODS: Methanol-Carnoy's-fixed colonic tissues, obtained from the stricture sites of 18 patients with Crohn's disease, were analyzed by immunostaining for vimentin, smooth muscle actin (1A4 and CGA7), angiotensin II type-1 receptor, angiotensin II-converting enzyme, and mast cell tryptase and chymase.
  • As controls, unaffected (normal) portions of 11 colonic tumor specimens were also investigated.
  • The majority of mesenchymal cells accumulated in the stricture lesions were moderately differentiated intestinal smooth muscle cells [vimentin(+), 1A4(+), and CGA7(+)].
  • Moreover, occasional intestinal smooth muscle cells in the muscular layers, adjacent to the site of the submucosal fibromuscular response, showed distinct positivity for vimentin, indicating phenotypic modulation toward an immature, or dedifferentiated state.
  • These smooth muscle cells accumulated in the stricture lesions were positive for angiotensin II type-1 receptor.
  • Abundant chymase-positive mast cells were distributed in these lesions.
  • CONCLUSIONS: These results suggest that the proliferation and migration of moderately differentiated intestinal smooth muscle cells from the muscular layers are the major pathological mechanisms in stricture formation in Crohn's disease, and the angiotensin II system is involved in this process.
  • [MeSH-major] Angiotensin II / metabolism. Constriction, Pathologic / pathology. Crohn Disease / pathology. Intestinal Mucosa / pathology
  • [MeSH-minor] Adult. Aged. Cell Movement. Cell Proliferation. Chymases / metabolism. Female. Humans. Male. Mast Cells / metabolism. Middle Aged. Myocytes, Smooth Muscle / metabolism. Phenotype

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thorax. 1999 Jan;54(1):88-90 [10343640.001]
  • [Cites] Inflamm Bowel Dis. 2004 Jan;10(1):55-60 [15058528.001]
  • [Cites] Am J Gastroenterol. 1962 May;37:541-5 [13907162.001]
  • [Cites] Lab Invest. 1987 Oct;57(4):359-69 [3669613.001]
  • [Cites] Circulation. 1991 Apr;83(4):1327-32 [2013150.001]
  • [Cites] Gut. 2005 Mar;54(3):349-56 [15710982.001]
  • [Cites] Br J Pharmacol. 2006 Mar;147(6):607-11 [16432510.001]
  • [Cites] Gastroenterology. 1990 Dec;99(6):1660-7 [2172072.001]
  • [Cites] J Cell Biol. 1985 Mar;100(3):807-13 [3972897.001]
  • [Cites] Cell. 1983 Aug;34(1):245-53 [6192933.001]
  • [Cites] Hepatol Res. 2005 Jun;32(2):107-16 [15905119.001]
  • [Cites] Circulation. 1997 Nov 18;96(10):3328-37 [9396424.001]
  • [Cites] Physiol Rev. 1997 Oct;77(4):1033-79 [9354811.001]
  • [Cites] Circ Res. 1991 Feb;68(2):450-6 [1991349.001]
  • [Cites] Gastroenterology. 1988 Feb;94(2):257-65 [3335305.001]
  • [Cites] J Hypertens. 1999 Apr;17(4):547-53 [10404957.001]
  • [Cites] Hypertens Res. 1997 Mar;20(1):51-5 [9101313.001]
  • [Cites] Hepatogastroenterology. 1990 Feb;37(1):18-31 [2179090.001]
  • [Cites] Histochem J. 1993 Jan;25(1):1-13 [7679380.001]
  • [Cites] Coron Artery Dis. 1995 Jan;6(1):71-81 [7767506.001]
  • [Cites] Gastroenterology. 1990 Jun;98(6):1543-8 [2159930.001]
  • [Cites] Virchows Arch. 1997 Nov;431(5):345-50 [9463576.001]
  • [Cites] J Med Genet. 2006 Oct;43(10):e51 [17047091.001]
  • [Cites] J Clin Gastroenterol. 1986 Oct;8(5):594-8 [3782760.001]
  • [Cites] Hum Pathol. 1980 Nov;11(6):620-34 [6161074.001]
  • [Cites] J Biol Chem. 1990 Dec 25;265(36):22348-57 [2266130.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):7127-31 [9054407.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jun;83(12):4464-8 [3520574.001]
  • [Cites] Am J Pathol. 1991 May;138(5):1233-42 [2024709.001]
  • [Cites] Histopathology. 2003 Dec;43(6):538-49 [14636254.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):46-50 [10636101.001]
  • [Cites] Am J Pathol. 1986 Oct;125(1):191-207 [3777135.001]
  • [Cites] Gut. 1999 Aug;45(2):210-7 [10403732.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Oct;279(4):G653-9 [11005750.001]
  • [Cites] J Cell Physiol. 2000 Feb;182(2):303-9 [10623895.001]
  • [Cites] Nature. 1991 May 16;351(6323):233-6 [2041570.001]
  • [Cites] Arch Pathol Lab Med. 2001 Oct;125(10):1331-4 [11570909.001]
  • [Cites] Clin Sci (Lond). 1981 Dec;61 Suppl 7:253s-256s [6172235.001]
  • [Cites] Inflamm Bowel Dis. 1995 Fall;1(3):220-7 [23282393.001]
  • [Cites] Gastroenterology. 1987 Feb;92(2):400-5 [3792777.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Dec;279(6):G1307-22 [11093955.001]
  • [Cites] Nature. 1968 Apr 13;218(5137):144-50 [4296306.001]
  • [Cites] Kidney Int. 2001 Apr;59(4):1374-81 [11260398.001]
  • [Cites] Regul Pept. 2005 Aug 15;130(1-2):67-74 [15908024.001]
  • [Cites] J Clin Invest. 1991 Aug;88(2):493-9 [1864960.001]
  • [Cites] Am J Gastroenterol. 2007 Feb;102(2):439-48 [17156147.001]
  • [Cites] Inflamm Bowel Dis. 2004 Sep;10(5):536-45 [15472513.001]
  • (PMID = 20361214.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11128-99-7 / Angiotensin II; EC 3.4.21.39 / Chymases
  •  go-up   go-down


73. Jain SP, Mehta DC, Shah SP, Singh PP, Amin PD: Melt-in-mouth pellets of fexofenadine hydrochloride using crospovidone as an extrusion-spheronisation aid. AAPS PharmSciTech; 2010 Jun;11(2):917-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microcrystalline cellulose (MCC) is well established as an extrusion spheronisation aid for the preparation of pellets.
  • Crospovidone was successfully employed as an extrusion-spheronisation aid to produce melt-in-mouth pellets obviating the need of a traditional extrusion-spheronisation aid, MCC.

  • Hazardous Substances Data Bank. TERFENADINE .
  • Hazardous Substances Data Bank. POLYVINYLPYRROLIDONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharm Dev Technol. 1999;4(4):499-505 [10578503.001]
  • [Cites] Eur J Pharm Sci. 2007 Jun;31(2):112-8 [17448646.001]
  • [Cites] Int J Pharm. 2001 Feb 1;213(1-2):7-12 [11165089.001]
  • [Cites] Eur J Pharm Sci. 2002 Apr;15(3):295-305 [11923062.001]
  • [Cites] Eur J Pharm Biopharm. 2002 Jul;54(1):95-9 [12084508.001]
  • [Cites] Int J Pharm. 2002 Oct 10;246(1-2):153-69 [12270618.001]
  • [Cites] Eur J Pharm Biopharm. 2003 Nov;56(3):371-80 [14602179.001]
  • [Cites] AAPS PharmSciTech. 2001;2(4):26 [14727863.001]
  • [Cites] Eur J Pharm Biopharm. 2004 Jan;57(1):107-14 [14729086.001]
  • [Cites] Eur J Pharm Sci. 2004 Feb;21(2-3):295-303 [14757501.001]
  • [Cites] Int J Pharm. 2004 May 4;275(1-2):41-60 [15081137.001]
  • [Cites] J Pharm Sci. 2004 Jul;93(7):1766-79 [15176065.001]
  • [Cites] J Pharm Sci. 1973 Jan;62(1):43-9 [4682932.001]
  • [Cites] J Pharm Sci. 1975 Oct;64(10):1688-92 [1185538.001]
  • [Cites] World Health Organ Tech Rep Ser. 1983;696:1-42 [6419473.001]
  • [Cites] J Pharm Sci. 1987 Dec;76(12):907-9 [3440935.001]
  • [Cites] J Pharm Pharmacol. 1988 Oct;40(10):674-8 [2907531.001]
  • [Cites] J Pharm Sci. 1993 Feb;82(2):220-6 [8445539.001]
  • [Cites] J Pharm Pharmacol. 1994 Jan;46(1):2-7 [8201523.001]
  • [Cites] Drugs. 1998 Feb;55(2):269-74; discussion 275-6 [9506246.001]
  • [Cites] Eur J Pharm Biopharm. 1998 Jan;45(1):57-65 [9689536.001]
  • [Cites] Eur J Pharm Sci. 1999 May;8(2):147-52 [10210738.001]
  • [Cites] Eur J Pharm Biopharm. 2005 Jan;59(1):127-31 [15567309.001]
  • [Cites] Eur J Pharm Biopharm. 2005 Apr;59(3):511-21 [15760732.001]
  • [Cites] Pharm Res. 2005 Aug;22(8):1387-98 [16078149.001]
  • [Cites] Int J Pharm. 2006 Jan 3;307(1):66-76 [16253448.001]
  • [Cites] Eur J Pharm Biopharm. 2006 May;63(1):68-75 [16325384.001]
  • [Cites] Eur J Pharm Biopharm. 2006 May;63(1):59-67 [16326085.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2006 Sep;54(9):1288-92 [16946537.001]
  • [Cites] Eur J Pharm Biopharm. 2007 Apr;66(1):83-94 [17045467.001]
  • [Cites] Drugs. 2000 Feb;59(2):301-21 [10730552.001]
  • (PMID = 20499219.001).
  • [ISSN] 1530-9932
  • [Journal-full-title] AAPS PharmSciTech
  • [ISO-abbreviation] AAPS PharmSciTech
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Capsules; 0 / Excipients; 7BA5G9Y06Q / Terfenadine; 9003-39-8 / Povidone; E6582LOH6V / fexofenadine
  • [Other-IDs] NLM/ PMC2902318
  •  go-up   go-down


74. Rawlings NG, Brownstein S, Jordan DR: Merkel cell carcinoma masquerading as a chalazion. Can J Ophthalmol; 2007 Jun;42(3):469-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma masquerading as a chalazion.
  • Histopathologic examination disclosed Merkel cell carcinoma (MCC).
  • COMMENTS: MCC must be included in the differential diagnosis of solitary eyelid nodules, requiring early and aggressive treatment.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17508048.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


75. Nilsson M, Strømme M: Electrodynamic investigations of conduction processes in humid microcrystalline cellulose tablets. J Phys Chem B; 2005 Mar 31;109(12):5450-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The conduction mechanism in microcrystalline cellulose (MCC) tablets at varying relative humidity (RH) has been investigated by using the techniques of low frequency dielectric spectroscopy and transient current analysis at room temperature.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16851580.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Excipients; 0 / microcrystalline cellulose; 9004-34-6 / Cellulose
  •  go-up   go-down


76. Zhang Q, Iwakuma N, Sharma P, Moudgil BM, Wu C, McNeill J, Jiang H, Grobmyer SR: Gold nanoparticles as a contrast agent for in vivo tumor imaging with photoacoustic tomography. Nanotechnology; 2009 Sep 30;20(39):395102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gold nanoparticles as a contrast agent for in vivo tumor imaging with photoacoustic tomography.
  • The ability to quantitatively and non-invasively image nanoparticles has important implications for the development of nanoparticles as in vivo cancer diagnostic and therapeutic agents.
  • In this study, the ability of systemically administered poly(ethylene glycol)-coated (PEGylated) gold nanoparticles as a contrast agent for in vivo tumor imaging with PAT has been evaluated.
  • Following intravenous administration of PEGylated gold nanoparticles to tumor-bearing mice, accumulation of gold nanoparticles in tumors can be effectively imaged with PAT.
  • With gold nanoparticles as a contrast agent, PAT has important potential applications in the image guided therapy of superficial tumors such as breast cancer, melanoma and Merkel cell carcinoma.

  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19726840.001).
  • [ISSN] 1361-6528
  • [Journal-full-title] Nanotechnology
  • [ISO-abbreviation] Nanotechnology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 7440-57-5 / Gold
  •  go-up   go-down


77. Koljonen V, Haglund C, Tukiainen E, Böhling T: Neuroendocrine differentiation in primary Merkel cell carcinoma--possible prognostic significance. Anticancer Res; 2005 Mar-Apr;25(2A):853-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine differentiation in primary Merkel cell carcinoma--possible prognostic significance.
  • BACKGROUND: The aim of this study was to examine the level of neuroendocrine differentiation to determine its association with clinicopathological parameters.
  • PATIENTS AND METHODS: Twenty-five primary MCC samples were evaluated for neuroendocrine differentiation profiles by immunohistochemistry using antibodies to chromogranin-A, microtubule associated protein-2 and synaptophysin.
  • RESULTS: In general, MCC shows a high degree of neuroendocrine differentiation.
  • Chromogranin-A appeared to be the most important one in predicting the course of disease.
  • CONCLUSION: Low levels of neuroendocrine differentiation in MCC associates with poor prognosis.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Neurosecretory Systems / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Differentiation / physiology. Chromogranin A. Chromogranins / biosynthesis. Female. Humans. Immunohistochemistry. Male. Microtubule-Associated Proteins / biosynthesis. Middle Aged. Prognosis. Synaptophysin / biosynthesis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868919.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins; 0 / MAP2 protein, human; 0 / Microtubule-Associated Proteins; 0 / Synaptophysin
  •  go-up   go-down


78. Morris KL, Williams B, Kennedy GA: Images in haematology. Heavy bone marrow involvement with metastatic Merkel cell tumour in an immunosuppressed renal transplant recipient. Br J Haematol; 2005 Jan;128(2):133
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images in haematology. Heavy bone marrow involvement with metastatic Merkel cell tumour in an immunosuppressed renal transplant recipient.
  • [MeSH-major] Bone Marrow Cells / pathology. Carcinoma, Merkel Cell / pathology. Carcinoma, Merkel Cell / secondary. Immunocompromised Host. Skin Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Chromogranin A. Chromogranins / analysis. Humans. Immunohistochemistry. Intermediate Filament Proteins / analysis. Keratin-20. Kidney Transplantation. Male. Polycystic Kidney Diseases / pathology. Polycystic Kidney Diseases / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2005 May;129(3):446 [15842673.001]
  • (PMID = 15638845.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Chromogranins; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / Keratin-20
  •  go-up   go-down


79. Kukko HM, Koljonen VS, Tukiainen EJ, Haglund CH, Böhling TO: Vascular invasion is an early event in pathogenesis of Merkel cell carcinoma. Mod Pathol; 2010 Aug;23(8):1151-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular invasion is an early event in pathogenesis of Merkel cell carcinoma.
  • This study investigated vascular and especially lymphovascular invasion in primary Merkel cell carcinoma and its value as a prognostic factor.
  • Paraffin-embedded blocks prepared from tumor samples obtained from 126 patients diagnosed with Merkel cell carcinoma in 1979-2004 were immunohistochemically stained using antibodies CD31 and D2-40 to detect intravascular tumor emboli.
  • This finding was compared with the clinical data and the disease outcome.
  • Intravascular tumor cells were observed in 117 (93%) of the samples.
  • The tumors lacking invasion were significantly smaller (P<0.01 and alpha=0.050) than those with vascular invasion, although lymphovascular invasion was observed even in the smallest tumor (0.3 cm) of this study.
  • Already in the early stages of the disease, Merkel cell carcinoma seems to have the capacity to penetrate vessel walls.
  • Our finding of the high frequency of lymphovascular invasion might therefore explain the extremely aggressive clinical behavior of Merkel cell carcinoma.
  • This may support the role of sentinel node biopsy even in the case of very small primary Merkel cell carcinoma tumors.
  • [MeSH-major] Carcinoma, Merkel Cell / blood supply. Neovascularization, Pathologic / pathology. Skin Neoplasms / blood supply
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal / metabolism. Antibodies, Monoclonal, Murine-Derived. Antigens, CD31 / metabolism. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20473275.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40
  •  go-up   go-down


80. Lu S, Li J, Song C, Shen K, Tseng GC: Biomarker detection in the integration of multiple multi-class genomic studies. Bioinformatics; 2010 Feb 1;26(3):333-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarker detection in the integration of multiple multi-class genomic studies.
  • MOTIVATION: Systematic information integration of multiple-related microarray studies has become an important issue as the technology becomes mature and prevalent in the past decade.
  • RESULTS: In this article, we develop three integration methods for biomarker detection in multiple multi-class microarray studies: ANOVA-maxP, min-MCC and OW-min-MCC.
  • Since P-values from ANOVA do not guarantee to reflect the concordant expression pattern information across studies, we propose a multi-class correlation (MCC) measure to specifically seek for biomarkers of concordant inter-class patterns across a pair of studies.
  • For both ANOVA and MCC approaches, we use extreme order statistics to identify biomarkers differentially expressed (DE) in all studies (i.e.
  • ANOVA-maxP and min-MCC).
  • The min-MCC method is further extended to identify biomarkers DE in partial studies by incorporating a recently developed optimally weighted (OW) technique (OW-min-MCC).
  • All methods are evaluated by simulation studies and by three meta-analysis applications to multi-tissue mouse metabolism datasets, multi-condition mouse trauma datasets and multi-malignant-condition human prostate cancer datasets.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2001 Jan 1;29(1):152-5 [11125075.001]
  • [Cites] BMC Bioinformatics. 2007;8:80 [17343745.001]
  • [Cites] Nucleic Acids Res. 2001 Jun 15;29(12):2549-57 [11410663.001]
  • [Cites] Stat Methods Med Res. 2001 Aug;10(4):267-76 [11491413.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):207-10 [11752295.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4427-33 [12154050.001]
  • [Cites] Bioinformatics. 2003;19 Suppl 1:i84-90 [12855442.001]
  • [Cites] Trends Genet. 2003 Oct;19(10):570-7 [14550631.001]
  • [Cites] Funct Integr Genomics. 2003 Dec;3(4):180-8 [12884057.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 [14711987.001]
  • [Cites] Biostatistics. 2004 Apr;5(2):155-76 [15054023.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2922-7 [15131026.001]
  • [Cites] Psychol Bull. 1951 May;48(3):156-8 [14834286.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D553-5 [15608260.001]
  • [Cites] BMC Bioinformatics. 2005;6:57 [15774008.001]
  • [Cites] J Bioinform Comput Biol. 2005 Oct;3(5):1171-89 [16278953.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] Biom J. 2006 Jun;48(3):435-50 [16845907.001]
  • [Cites] Bioinformatics. 2006 Nov 15;22(22):2825-7 [16982708.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • (PMID = 19965884.001).
  • [ISSN] 1367-4811
  • [Journal-full-title] Bioinformatics (Oxford, England)
  • [ISO-abbreviation] Bioinformatics
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / KL2 RR024154; United States / NCRR NIH HHS / RR / KL2 RR024154-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  • [Other-IDs] NLM/ PMC2815659
  •  go-up   go-down


81. Marcantoni A, Vandael DH, Mahapatra S, Carabelli V, Sinnegger-Brauns MJ, Striessnig J, Carbone E: Loss of Cav1.3 channels reveals the critical role of L-type and BK channel coupling in pacemaking mouse adrenal chromaffin cells. J Neurosci; 2010 Jan 13;30(2):491-504
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of Cav1.3 channels reveals the critical role of L-type and BK channel coupling in pacemaking mouse adrenal chromaffin cells.
  • We studied wild-type (WT) and Cav1.3(-/-) mouse chromaffin cells (MCCs) with the aim to determine the isoform of L-type Ca(2+) channel (LTCC) and BK channels that underlie the pacemaker current controlling spontaneous firing.
  • Most WT-MCCs (80%) were spontaneously active (1.5 Hz) and highly sensitive to nifedipine and BayK-8644 (1,4-dihydro-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-3-pyridinecarboxylic acid, methyl ester).
  • The two dihydropyridines and the BK channel blocker paxilline altered the shape of action potentials (APs), suggesting close coupling of LTCCs to BK channels.
  • WT-MCCs expressed equal fractions of functionally active Cav1.2 and Cav1.3 channels.
  • Cav1.3 channel deficiency decreased the number of normally firing MCCs (30%; 2.0 Hz), suggesting a critical role of these channels on firing, which derived from their slow inactivation rate, sizeable activation at subthreshold potentials, and close coupling to fast inactivating BK channels as determined by using EGTA and BAPTA Ca(2+) buffering.
  • By means of the action potential clamp, in TTX-treated WT-MCCs, we found that the interpulse pacemaker current was always net inward and dominated by LTCCs.
  • Deletion of Cav1.3 channels reduced drastically the inward Ca(2+) current and the corresponding Ca(2+)-activated BK current during spikes.
  • Our data highlight the role of Cav1.3, and to a minor degree of Cav1.2, as subthreshold pacemaker channels in MCCs and open new interesting features about their role in the control of firing and catecholamine secretion at rest and during sustained stimulations matching acute stress.
  • [MeSH-major] Adrenal Medulla / cytology. Calcium Channels, L-Type / deficiency. Calcium Channels, L-Type / metabolism. Chromaffin Cells / physiology. Large-Conductance Calcium-Activated Potassium Channels / metabolism
  • [MeSH-minor] 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / pharmacology. Adrenal Cortex / metabolism. Animals. Biophysical Phenomena / drug effects. Biophysical Phenomena / genetics. Biophysics. Calcium Channel Agonists / pharmacology. Calcium Channel Blockers / pharmacology. Cells, Cultured. Chelating Agents / pharmacology. Dose-Response Relationship, Drug. Egtazic Acid / analogs & derivatives. Egtazic Acid / pharmacology. Electric Stimulation / methods. Gene Expression Regulation / drug effects. Gene Expression Regulation / genetics. Indoles / pharmacology. Ionophores / pharmacology. Membrane Potentials / drug effects. Membrane Potentials / genetics. Mice. Mice, Knockout. Patch-Clamp Techniques. Potassium Channel Blockers / pharmacology. Spider Venoms / pharmacology. Time Factors

  • Guide to Pharmacology. gene/protein/disease-specific - Cav1.3 - data and references .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20071512.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / P 20670
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CACNA1C protein, mouse; 0 / Cacna1d protein, mouse; 0 / Calcium Channel Agonists; 0 / Calcium Channel Blockers; 0 / Calcium Channels, L-Type; 0 / Chelating Agents; 0 / Indoles; 0 / Ionophores; 0 / L-type calcium channel alpha(1C); 0 / Large-Conductance Calcium-Activated Potassium Channels; 0 / Potassium Channel Blockers; 0 / SNX 482; 0 / Spider Venoms; 3T9U9Z96L7 / paxilline; 526U7A2651 / Egtazic Acid; 71145-03-4 / 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; K22DDW77C0 / 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid
  •  go-up   go-down


82. Jouary T, Lalanne N, Siberchicot F, Ricard AS, Versapuech J, Lepreux S, Delaunay M, Taieb A: Neoadjuvant polychemotherapy in locally advanced Merkel cell carcinoma. Nat Rev Clin Oncol; 2009 Sep;6(9):544-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant polychemotherapy in locally advanced Merkel cell carcinoma.
  • BACKGROUND: A 72-year-old man presented with a Merkel cell carcinoma (MCC) of the left cheek with concomitant nodal spread.
  • A 61-year-old man presented with an MCC of the right thigh with rapid nodal recurrence.
  • INVESTIGATIONS: Skin biopsy samples proved the MCC nature of the neoplasm in both patients.
  • DIAGNOSIS: Advanced stage II MCC.
  • Nodal and cutaneous recurrences were treated with a neoadjuvant EPC regimen leading to a 5-year complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Merkel Cell / drug therapy. Carcinoma, Merkel Cell / pathology. Carcinoma, Merkel Cell / radiotherapy. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19707243.001).
  • [ISSN] 1759-4782
  • [Journal-full-title] Nature reviews. Clinical oncology
  • [ISO-abbreviation] Nat Rev Clin Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


83. Weeraratna AT, Houben R, O'Connell MP, Becker JC: Lack of Wnt5A expression in Merkel cell carcinoma. Arch Dermatol; 2010 Jan;146(1):88-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of Wnt5A expression in Merkel cell carcinoma.
  • [MeSH-major] Carcinoma, Merkel Cell / genetics. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Proto-Oncogene Proteins / genetics. Skin Neoplasms / genetics. Wnt Proteins / genetics
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Humans. Immunohistochemistry. Polymerase Chain Reaction. Wnt-5a Protein

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20083703.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 AI999999; United States / Intramural NIH HHS / /
  • [Publication-type] Letter; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Proto-Oncogene Proteins; 0 / WNT5A protein, human; 0 / Wnt Proteins; 0 / Wnt-5a Protein
  •  go-up   go-down


84. Heath ML, Nghiem P: Merkel cell carcinoma: if no breslow, then what? J Surg Oncol; 2007 Jun 15;95(8):614-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma: if no breslow, then what?
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Skin / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Surg Oncol. 2007 Jun 15;95(8):618-22 [17345617.001]
  • (PMID = 17221860.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


85. Metlitskaya A, Kazakov T, Vondenhoff GH, Novikova M, Shashkov A, Zatsepin T, Semenova E, Zaitseva N, Ramensky V, Van Aerschot A, Severinov K: Maturation of the translation inhibitor microcin C. J Bacteriol; 2009 Apr;191(7):2380-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microcin C (McC), an inhibitor of the growth of enteric bacteria, consists of a heptapeptide with a modified AMP residue attached to the backbone of the C-terminal aspartate through an N-acyl phosphamidate bond.
  • Here we identify maturation intermediates produced by cells lacking individual mcc McC biosynthesis genes.
  • We show that the products of the mccD and mccE genes are required for attachment of a 3-aminopropyl group to the phosphate of McC and that this group increases the potency of inhibition of the McC target, aspartyl-tRNA synthetase.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1999 Nov 15;18(22):6532-41 [10562565.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Sep;47(9):2868-74 [12936987.001]
  • [Cites] J Bacteriol. 1978 Aug;135(2):342-7 [355221.001]
  • [Cites] Nature. 1994 May 26;369(6478):281 [8183363.001]
  • [Cites] J Biol Chem. 1995 Oct 6;270(40):23520-32 [7559516.001]
  • [Cites] Bioorg Med Chem. 2005 Jan 3;13(1):69-75 [15582453.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1533 [16141066.001]
  • [Cites] J Biol Chem. 2006 Jun 30;281(26):18033-42 [16574659.001]
  • [Cites] J Bacteriol. 2007 Mar;189(5):2114-8 [17158672.001]
  • [Cites] Mol Microbiol. 2007 Sep;65(6):1380-94 [17711420.001]
  • [Cites] Proteins. 2007 Nov 1;69(2):349-57 [17623865.001]
  • [Cites] J Bacteriol. 2007 Nov;189(22):8361-5 [17873039.001]
  • [Cites] J Am Chem Soc. 2008 Mar 19;130(11):3603-9 [18290647.001]
  • [Cites] J Bacteriol. 2008 Apr;190(7):2607-10 [18223070.001]
  • (PMID = 19168611.001).
  • [ISSN] 1098-5530
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / U54 AI057158
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacteriocins; 0 / Escherichia coli Proteins; 0 / Protein Synthesis Inhibitors; 1403-96-9 / microcin; EC 6.1.1.12 / Aspartate-tRNA Ligase
  • [Other-IDs] NLM/ PMC2655510
  •  go-up   go-down


86. Wang L, Detamore MS: Effects of growth factors and glucosamine on porcine mandibular condylar cartilage cells and hyaline cartilage cells for tissue engineering applications. Arch Oral Biol; 2009 Jan;54(1):1-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of growth factors and glucosamine on porcine mandibular condylar cartilage cells and hyaline cartilage cells for tissue engineering applications.
  • Temporomandibular joint (TMJ) condylar cartilage is a distinct cartilage that has both fibrocartilaginous and hyaline-like character, with a thin proliferative zone that separates the fibrocartilaginous fibrous zone at the surface from the hyaline-like mature and hypertrophic zones below.
  • In this study, we compared the effects of insulin-like growth factor-I (IGF-I), basic fibroblast growth factor (bFGF), transforming growth factor beta1 (TGF-beta1), and glucosamine sulphate on porcine TMJ condylar cartilage and ankle cartilage cells in monolayer culture.
  • In general, TMJ condylar cartilage cells proliferated faster than ankle cartilage cells, while ankle cells produced significantly greater amounts of glycosaminoglycans (GAGs) and collagen than TMJ condylar cartilage cells.
  • IGF-I and bFGF were potent stimulators of TMJ cell proliferation, while no signals statistically outperformed controls for ankle cell proliferation.
  • IGF-I was the most effective signal for GAG production with ankle cells, and the most potent upregulator of collagen synthesis for both cell types.
  • Glucosamine sulphate promoted cell proliferation and biosynthesis at specific concentrations and outperformed growth factors in certain instances.
  • In conclusion, hyaline cartilage cells had lower cell numbers and superior biosynthesis compared to TMJ condylar cartilage cells, and we have found IGF-I at 100 ng/mL and glucosamine sulphate at 100 microg/mL to be the most effective signals for these cells under the prescribed conditions.
  • [MeSH-major] Cartilage / drug effects. Intercellular Signaling Peptides and Proteins / pharmacology. Transforming Growth Factor beta / biosynthesis
  • [MeSH-minor] Animals. Cell Proliferation. Female. Fibroblast Growth Factor 2 / pharmacology. Glucosamine / pharmacology. Hyaline Cartilage / cytology. Hyaline Cartilage / drug effects. Hyaline Cartilage / metabolism. Insulin-Like Growth Factor I / pharmacology. Mandibular Condyle / cytology. Swine. Temporomandibular Joint. Tissue Engineering / methods. Transforming Growth Factor beta1 / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUCOSAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18640663.001).
  • [ISSN] 1879-1506
  • [Journal-full-title] Archives of oral biology
  • [ISO-abbreviation] Arch. Oral Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; 103107-01-3 / Fibroblast Growth Factor 2; 67763-96-6 / Insulin-Like Growth Factor I; N08U5BOQ1K / Glucosamine
  •  go-up   go-down


87. Kobylianskiĭ VI, Gamal' EA: [Mucoactive therapy and new aspects of the pathogenesis of chronic obstructive pulmonary disease]. Klin Med (Mosk); 2006;84(8):15-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucoactive therapy and new aspects of the pathogenesis of chronic obstructive pulmonary disease].
  • From the present-day view, the article considers the potential of mucoactive therapy, directed towards the correction of mucociliary clearance (MCC) as the leading protective mechanism of the respiratory organs.
  • Despite the big number of therapeutic agents and methods affecting the mucous link of the mucociliary system, not many of them, according to direct non-invasive in vivo studies, have a significant effect on MCC; physiotherapeutic methods have certain advantages.
  • Chronic obstructive pulmonary disease model is used to demonstrate new aspects of the pathogenesis of chronic inflammatory process in the lungs.
  • [MeSH-major] Drug Therapy / methods. Mucociliary Clearance / drug effects. Pulmonary Disease, Chronic Obstructive / physiopathology. Pulmonary Disease, Chronic Obstructive / therapy


88. Tucci MG, Lucarini G, Giangiacomi M, Zizzi A, Criante P, Ricotti G, Biagini G: Immunohistochemical study of apoptosis markers and involvement of chemokine CXCR4 in skin Merkel cell carcinoma. J Eur Acad Dermatol Venereol; 2006 Nov;20(10):1220-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical study of apoptosis markers and involvement of chemokine CXCR4 in skin Merkel cell carcinoma.
  • BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive cancer of the skin that mainly affects elderly patients.
  • Immunohistochemical expression of apoptosis proteins is considered a useful marker of both malignancy and tumour progression.
  • Apoptosis plays a fundamental role in skin homeostasis, and apoptotic cells have been detected in normal and diseased skin.
  • Chemokines possess a wide range of biological activities and CXCR4 is expressed in some cancer cells, where it plays an efficient role in metastasis formation.
  • OBJECTIVE: To identify immunohistochemical parameters that can help clinicians select the most suitable therapy for skin MCC.
  • METHODS: Immunohistochemical detection of apoptosis inhibitors and CXCR4 was performed on tissue from 12 patients with primary MCC.
  • After excision of the primary lesion, five survived and had no metastases, and seven experienced local recurrence or lymph node metastases.
  • CONCLUSIONS: Our results show strong MCC cell apoptosis inhibition and a high cell proliferation capacity.
  • The positive correlation between survivin and p53 may be a predictor of MCC spread via the lymphatic network.
  • [MeSH-major] Apoptosis. Carcinoma, Merkel Cell / metabolism. Carcinoma, Merkel Cell / pathology. Receptors, CXCR4 / metabolism. Skin Neoplasms / metabolism. Skin Neoplasms / pathology
  • [MeSH-minor] Biomarkers / metabolism. Biomarkers, Tumor / metabolism. Cell Division. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Ki-67 Antigen / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Predictive Value of Tests. Prognosis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062035.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Inhibitor of Apoptosis Proteins; 0 / Ki-67 Antigen; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, CXCR4; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


89. Conley M, Hawkins K, Ririe D: Complete heart block and cardiac tamponade secondary to Merkel cell carcinoma cardiac metastases. South Med J; 2006 Jan;99(1):74-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete heart block and cardiac tamponade secondary to Merkel cell carcinoma cardiac metastases.
  • This is a unique case of Merkel cell carcinoma, a rare neuroendocrine tumor, metastasizing to the heart and inducing a progression of cardiac complications such as new-onset atrial fibrillation, malignant pericardial effusion with tamponade physiology, first-degree heart block, and complete heart block.
  • This is the first case report of cardiac metastases from Merkel cell carcinoma causing cardiac tamponade or complete heart block.
  • This case highlights the clinical decision-making involved in managing cardiac tamponade and complete heart block in the setting of metastatic disease to the heart.
  • [MeSH-major] Carcinoma, Merkel Cell / complications. Cardiac Tamponade / etiology. Heart Block / etiology. Heart Neoplasms / complications. Skin Neoplasms / complications
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Echocardiography, Transesophageal. Electrocardiography. Fatal Outcome. Follow-Up Studies. Heart Atria / pathology. Heart Atria / radiography. Heart Atria / ultrasonography. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] South Med J. 2006 Jan;99(1):4 [16466106.001]
  • (PMID = 16466126.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Esen BA, Pinarbasi B, Buyukbabani N, Baykal C, Cizmeci O, Demir K, Acarli K, Kaymakoglu S: Merkel-cell carcinoma arising after liver transplantation: a case report. Transplant Proc; 2005 Dec;37(10):4413-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel-cell carcinoma arising after liver transplantation: a case report.
  • Merkel-cell carcinoma is a rare and an aggressive neuroendocrine tumour of the skin that has been reported to be common in transplant recipients.
  • Herein, a 25-year-old woman who developed Merkel-cell carcinoma after liver transplantation is reported.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Carcinoma, Merkel Cell / surgery. Cholangitis, Sclerosing / surgery. Liver Transplantation / adverse effects. Postoperative Complications / pathology
  • [MeSH-minor] Adult. Female. Humans. Treatment Outcome


91. Bolsunovskiĭ AIa, Muratova EN, Sukovatyĭ AG, Pimenov AV, Sanzharaeva EA, Zotina TA, Sedel'nikova TS, Pan'kov EV, Kornilova MG: [Radioecological monitoring of the Yenisei River and citological characterization of a submerged aquatic plant Elodea canadensis]. Radiats Biol Radioecol; 2007 Jan-Feb;47(1):63-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The samples were collected in the area subjected to radioactive impact of the Mining-and-Chemical Combine (MCC) at Zheleznogorsk and in the control area, upstream of the MCC.
  • The investigations shown that elodea biomass in the area affected by MCC operation contained a long inventory of artificial radionuclides typical for the MCC discharges.
  • The upstream of the MCC, in the control sampling area, the sediments and the elodea biomass contained only one artificial radionuclide--137Cs.
  • Thus, the exposure doses to elodea shoots and roots upstream of the MCC are small (not more than 8 microGy/d) and the main contribution info the dose is made by natural radionuclides.
  • At the MCC discharge site (the village of Atamanovo) and at the downstream of it, the total dose rate increases almost an order of magnitude, reaching its maximal values--72 microGy/d for elodea shoots and 58 microGy/d for its roots.
  • Cytogenetic investigations of elodea roots shown that at the MCC discharge site (the village of Atamanovo) and at downstream of it the occurrence of chromosomal aberrations in ana-telophase and in metaphase cells of elodea was considerably higher than in the control area.

  • MedlinePlus Health Information. consumer health - Water Pollution.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17387996.001).
  • [ISSN] 0869-8031
  • [Journal-full-title] Radiatsionnaia biologiia, radioecologiia
  • [ISO-abbreviation] Radiats Biol Radioecol
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Cesium Radioisotopes; 0 / Metals, Heavy; 0 / Water Pollutants, Chemical; 0 / Water Pollutants, Radioactive
  •  go-up   go-down


92. Capel F, Demaison L, Maskouri F, Diot A, Buffiere C, Patureau Mirand P, Mosoni L: Calcium overload increases oxidative stress in old rat gastrocnemius muscle. J Physiol Pharmacol; 2005 Sep;56(3):369-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to challenge in vivo muscle Ca2+ homeostasis and analyze consequences on mitochondrial H2O2 release (MHR) and sarcopenia, we injected Ca2+ ionophore A23187 (200 microg/kg, ip) in adult and old rats and measured gastrocnemius mass and mitochondrial Ca2+ content (MCC) using radioactive Ca2+ 48 h after injection.
  • In a second experiment performed in old rats, we measured isocitrate dehydrogenase (ICDH) activity as an index of MCC, MHR, mitochondrial respiration, citrate synthase, COX and antioxydant enzyme activities 24 h after a 150 microg/kg injection.
  • In adult rats, muscle mass and MCC were unchanged by A23187.
  • In old rats, MCC increased 24 h after injection as reflected by a significant increase in ICDH activity; measured MCC tended to increase at 48 h.
  • Muscle mass was unchanged but was negatively correlated with MCC in control and treated old rats.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16204760.001).
  • [ISSN] 0867-5910
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Ionophores; 37H9VM9WZL / Calcimycin; BBX060AN9V / Hydrogen Peroxide; SY7Q814VUP / Calcium
  •  go-up   go-down


93. Brandl C, Kaesbauer J, Weber BH, Morsczeck C: Spontaneous immortalization of neural crest-derived corneal progenitor cells after chromosomal aberration. Cell Prolif; 2010 Aug;43(4):372-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous immortalization of neural crest-derived corneal progenitor cells after chromosomal aberration.
  • OBJECTIVES: In a previous study, we have reported the existence of neural crest-derived stem cell-like cells originating from the corneal limbus of juvenile mice (termed murine corneal cells, MCCs).
  • To yield a sufficient number of MCCs, for example, for cell-therapy approaches, here we have investigated MCCs' ability for extensive proliferation, and we have evaluated their stem cell qualities and genetic stability after large-scale culture.
  • MATERIALS AND METHODS: MCCs were established from corneal limbal tissue of juvenile mice.
  • To determine their cell proliferation and self-renewing potential, MTT tests and an estimation of colony forming unit efficiency were carried out.
  • Multipotency of cell differentiation was examined by applying adipogenic and osteogenic differentiation protocols.
  • Moreover, karyotyping was performed and expression of stem cell markers and cell cycle-associated genes was analysed.
  • RESULTS: MCCs, as primary cells, could be cultured for more than 60 passages.
  • We observed increased cell proliferation and high number of colony forming units (CFUs) after extensive culture.
  • Interestingly, there were no changes in expression of MCC markers.
  • Furthermore, cell differentiation potentials remained comparable with MCCs at early passages.
  • Moreover, tumour suppressor genes such as p16 and p21 were found to be down-regulated after large-scale cell culture.
  • CONCLUSIONS: MCCs immortalize spontaneously after extensive cell culture, but still demonstrate stem cell-like qualities.
  • [MeSH-major] Limbus Corneae / cytology. Stem Cells / cytology. Stem Cells / metabolism
  • [MeSH-minor] Animals. Cell Culture Techniques. Cell Differentiation / genetics. Cell Proliferation. Chromosome Aberrations. Cornea. Karyotyping. Mice. Mice, Inbred C57BL. Multipotent Stem Cells / metabolism. Neurons / cytology. Neurons / metabolism

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20590662.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


94. Cheuk W, Chan JK: Advances in salivary gland pathology. Histopathology; 2007 Jul;51(1):1-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review summarizes the new findings on salivary gland pathology under the following categories: immunohistochemistry; molecular genetics; newly recognized tumour types; known tumour entities with new findings; and progression of salivary gland tumours.
  • In the application of immunohistochemistry, CD117 can aid in highlighting the luminal cell component of various salivary gland tumours, whereas p63 or maspin can aid in highlighting the abluminal cell component.
  • A high Ki67 index remains the most useful marker to predict adverse outcome in salivary gland carcinoma.
  • Specific chromosomal translocations are recognized in pleomorphic adenoma (with translocation involving PLGA1 or HMGA2 gene) and mucoepidermoid carcinoma (with MECT1-MAML2 gene fusion).
  • Newly recognized entities include: sclerosing polycystic adenosis (with recent molecular evidence supporting its neoplastic nature), sclerosing mucoepidermoid carcinoma with eosinophilia, keratocystoma, adenoma with additional stromal component (lymphadenoma, lipoadenoma and adenofibroma), cribriform adenocarcinoma of the tongue and signet ring adenocarcinoma of minor salivary gland.
  • Known tumour entities with new findings include: salivary duct carcinoma (with newly recognized mucinous, micropapillary and sarcomatoid variants), intraductal carcinoma (with controversies in terminology), mucoepidermoid carcinoma (with newly proposed grading parameters and oncocytic variant), epithelial-myoepithelial carcinoma (with newly recognized morphological variants), small cell carcinoma (with most cases being related to Merkel cell carcinoma), extranodal marginal zone B-cell lymphoma (with specific chromosomal translocation) and chronic sclerosing sialadenitis (being a component of IgG4-related sclerosing disease).
  • Progression of salivary gland tumours can take the form of malignant transformation of a benign tumour, progression from low-grade to high-grade carcinoma, dedifferentiation, or stromal invasion of an in situ carcinoma.
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Disease Progression. Gene Expression Regulation, Neoplastic. Humans

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17539914.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 142
  •  go-up   go-down


95. Prabhu S, Smitha RS, Punnya VA: Merkel cell carcinoma of the alveolar mucosa in a young adult: a rare case report. Br J Oral Maxillofac Surg; 2010 Jan;48(1):48-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma of the alveolar mucosa in a young adult: a rare case report.
  • Merkel cell carcinoma (MCC) is an extremely rare and aggressive primary neuroendocrine neoplasm of the skin with a poor prognosis.
  • We report a rare case of MCC that arose in the alveolar mucosa of a young adult.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Mouth Mucosa / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Adult. Alveolar Process / pathology. Chromogranins / analysis. Follow-Up Studies. Humans. Keratin-3 / analysis. Lymphatic Metastasis / pathology. Male. Mouth Floor / pathology. Oral Ulcer / pathology. Radiography, Panoramic

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19167791.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Chromogranins; 0 / KRT3 protein, human; 0 / Keratin-3
  •  go-up   go-down


96. Sun CC: True density of microcrystalline cellulose. J Pharm Sci; 2005 Oct;94(10):2132-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microcrystalline cellulose (MCC) exhibits unusual tableting properties, sometimes, inconsistent with its high plasticity.
  • It is found that some of the unusual tableting properties of MCC can be explained in part by the use of inaccurate true density during tableting data analysis.
  • MCC true density as a function of water content is determined using a published method that can determine true density of water containing solids.
  • Results suggest that literature MCC true densities tend to be overestimated as a result of limitations in helium pycnometry.

  • Hazardous Substances Data Bank. Water .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc. and the American Pharmacists Association
  • (PMID = 16136576.001).
  • [ISSN] 0022-3549
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Excipients; 0 / Powders; 0 / Tablets; 0 / microcrystalline cellulose; 059QF0KO0R / Water; 9004-34-6 / Cellulose
  •  go-up   go-down


97. Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, Johnson TM, Liegeois-Kwon NJ, Otley CC, Paulson KG, Ross MI, Yu SS, Zeitouni NC, Byrd DR, Sondak VK, Gershenwald JE, Sober AJ, Nghiem P: Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol; 2010 Nov;63(5):751-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system.
  • BACKGROUND: The management of Merkel cell carcinoma (MCC) has been complicated by a lack of detailed prognostic data and by the presence of conflicting staging systems.
  • OBJECTIVE: We sought to determine the prognostic significance of tumor size, clinical versus pathologic nodal evaluation, and extent of disease at presentation and thereby derive the first consensus staging/prognostic system for MCC.
  • METHODS: A total of 5823 prospectively enrolled MCC cases from the National Cancer Data Base had follow-up data (median 64 months) and were used for prognostic analyses.
  • Among all MCC cases, 66% presented with local, 27% with nodal, and 7% with distant metastatic disease.
  • For cases presenting with local disease only, smaller tumor size was associated with better survival (stage I, ≤2 cm, 66% relative survival at 5 years; stage II, >2 cm, 51%; P < .0001).
  • Patients with clinically local-only disease and pathologically proven negative nodes had better outcome (76% at 5 years) than those who only underwent clinical nodal evaluation (59%, P < .0001).
  • LIMITATIONS: The National Cancer Data Base does not capture disease-specific survival.
  • Overall survival for patients with MCC was therefore used to calculate relative survival based on matched population data.
  • CONCLUSION: Although the majority (68%) of patients with MCC in this nationwide cohort did not undergo pathologic nodal evaluation, this procedure may be indicated in many cases as it improves prognostic accuracy and has important treatment implications for those found to have microscopic nodal involvement.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • [Cites] Semin Urol Oncol. 2002 May;20(2):108-15 [12012296.001]
  • [Cites] J Am Acad Dermatol. 2008 Mar;58(3):375-81 [18280333.001]
  • [Cites] Stat Med. 2004 Jan 15;23(1):51-64 [14695639.001]
  • [Cites] Arch Surg. 1991 Dec;126(12):1514-9 [1842182.001]
  • [Cites] Ann Surg. 1999 Jan;229(1):97-105 [9923806.001]
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):1-4 [15611998.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2300-9 [15800320.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):685-90 [16785370.001]
  • [Cites] Head Neck. 2007 Mar;29(3):249-57 [17163472.001]
  • [Cites] J Invest Dermatol. 2007 Sep;127(9):2100-3 [17700621.001]
  • [Cites] Ann Surg Oncol. 2008 Mar;15(3):683-90 [18183467.001]
  • [Cites] Br J Surg. 2008 Mar;95(3):302-9 [17876750.001]
  • [Cites] Science. 2008 Feb 22;319(5866):1096-100 [18202256.001]
  • [Cites] Cancer. 2008 Nov 1;113(9):2549-58 [18798233.001]
  • [Cites] J Surg Oncol. 2009 Apr 1;99(5):269-72 [19170124.001]
  • [Cites] Actas Dermosifiliogr. 2009 Dec;100 Suppl 2:49-54 [20096162.001]
  • [Cites] Arch Pathol Lab Med. 2010 Mar;134(3):341-4 [20196661.001]
  • [Cites] J Cutan Pathol. 2010 Jan;37(1):20-7 [19638070.001]
  • [Cites] Cancer. 2001 Apr 15;91(8 Suppl):1589-92 [11309755.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] Lancet. 2002 Feb 9;359(9305):497-8 [11853800.001]
  • [Cites] J Am Acad Dermatol. 2003 Nov;49(5):832-41 [14576661.001]
  • (PMID = 20646783.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / RC2 CA147820; United States / NIAMS NIH HHS / AR / K02 AR050993; United States / NCI NIH HHS / CA / K24 CA139052; United States / NCI NIH HHS / CA / K24-CA139052; United States / NCI NIH HHS / CA / T32 CA080416; United States / NIAMS NIH HHS / AR / K02-AR50993
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS191095; NLM/ PMC2956767
  •  go-up   go-down


98. Lucandri G, Mazzocchi P, Bascone B, Giordano M, Castaldi M, Lazzarini A, Carotenuto F: Unusual ulcerated Merkel cell carcinoma of the skin: report of a case. Tumori; 2006 Nov-Dec;92(6):555-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual ulcerated Merkel cell carcinoma of the skin: report of a case.
  • Merkel cell carcinoma is an aggressive skin cancer, usually related to a severe prognosis.
  • Herein we report the case of a patient treated for a wide bleeding and ulcerated Merkel cell carcinoma.
  • Ulceration represents an uncommon feature because the tumor usually spreads from the dermis into subcutaneous fat, so it may be added to poor prognostic indicators.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Skin Neoplasms / pathology. Skin Ulcer / etiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17260502.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Robert C: [What is new in oncodermatology?]. Ann Dermatol Venereol; 2008 Dec;135 Suppl 7:S354-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Quoi de neuf en cancérologie cutanée?
  • Besides melanoma, the scoop of the year was the discovery of a defective oncogenic polyomavirus which is very likely to be responsible for Merkel cell carcinoma.
  • [MeSH-major] Dermatology / trends. Medical Oncology / trends. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carcinoma, Merkel Cell / drug therapy. Carcinoma, Merkel Cell / virology. Clinical Trials as Topic. Evidence-Based Medicine. Humans. Interferon-alpha / therapeutic use. Patient Selection. Polyomavirus / isolation & purification. Prognosis. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19264211.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


100. Salvador Alonso R, Lahbabi I, Ben Hassel M, Boisselier P, Chaari N, Lesimple T, Chevrier S, de Crevoisier R: [Merkel cell carcinoma: outcome and role of radiotherapy]. Cancer Radiother; 2008 Sep;12(5):352-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Merkel cell carcinoma: outcome and role of radiotherapy].
  • [Transliterated title] Carcinome à cellules de Merkel : prise en charge et place de la radiothérapie.
  • Merkel cell carcinoma (MCC) are rare neuroendocrine malignant tumor of the skin, occurring in elderly patients.
  • It affects primarily the sun-exposed areas of the skin, with approximately 50% of all tumors occurring in the face and neck and 40% in the extremities.
  • Immunohistochemical markers (CK20+, CK7- and TTF1-) are used to distinguish between MCC and other tumors.
  • MCC have a tendency to rapid local progression, frequent spread to regional lymph nodes and distant metastases.
  • Due to the rarity of the disease, the optimal treatment has not been fully defined.
  • Localized stages (stages I and II) are treated by surgical excision of the primary tumor (with 2 to 3 cm margin) and lymphadenectomy in case of node-positive disease, followed by external beam radiotherapy (EBRT) to a total dose of 50 to 60Gy in the tumor bed.
  • Chemotherapy is recommended only for metastatic disease.
  • [MeSH-major] Carcinoma, Merkel Cell / radiotherapy. Skin Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18511325.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 68
  •  go-up   go-down






Advertisement